Review

Polyamine Metabolism and Gene Methylation in Conjunction with One-Carbon Metabolism

Kuniyasu Soda

Cardiovascular Research Institute, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma, Omiya, Saitama-city, Saitama Prefecture 330-8503, Japan; soda@jichi.ac.jp; Tel.: +81-48-647-2111

Received: 14 September 2018; Accepted: 5 October 2018; Published: 10 October 2018

Abstract: Recent investigations have revealed that changes in DNA methylation status play an important role in aging-associated pathologies and lifespan. The methylation of DNA is regulated by DNA methyltransferases (DNMT1, DNMT3a, and DNMT3b) in the presence of S-adenosylmethionine (SAM), which serves as a methyl group donor. Increased availability of SAM enhances DNMT activity, while its metabolites, S-adenosyl-L-homocysteine (SAH) and decarboxylated S-adenosylmethionine (dcSAM), act to inhibit DNMT activity. SAH, which is converted from SAM by adding a methyl group to cytosine residues in DNA, is an intermediate precursor of homocysteine. dcSAM, converted from SAM by the enzymatic activity of adenosylmethionine decarboxylase, provides an aminopropyl group to synthesize the polyamines spermine and spermidine. Increased homocysteine levels are a significant risk factor for the development of a wide range of conditions, including cardiovascular diseases. However, successful homocysteine-lowering treatment by vitamins (B6, B12, and folate) failed to improve these conditions. Long-term increased polyamine intake elevated blood spermine levels and inhibited aging-associated pathologies in mice and humans. Spermine reversed changes (increased dcSAM, decreased DNMT activity, aberrant DNA methylation, and proinflammatory status) induced by the inhibition of ornithine decarboxylase. The relation between polyamine metabolism, one-carbon metabolism, DNA methylation, and the biological mechanism of spermine-induced lifespan extension is discussed.

Keywords: polyamine; spermine; spermidine; methylation; DNA; lymphocyte function-associated antigen 1 (LFA-1); LFA-1 promoter (ITGAL); one carbon metabolism; DNA methyltransferases (DNMT)

1. Introduction

Aging is associated with declines in physiological function, altered immune function, increased proinflammatory status, and increased susceptibility to pathologies such as cardiovascular disease, cancer, sarcopenia, and metabolic and neurodegenerative diseases. The prevalence of aging-associated diseases and life-span ranges widely, even in countries and areas with similar social and economic conditions. For example, among European and Western countries, there are significant differences in both life expectancy at birth and the incidence of cardiovascular diseases (CVDs), one of the most frequent aging-associated conditions. There is also a close inverse correlation between life expectancy and age-standardized mortality rates due to CVDs [1]. Epidemiological analyses and interventional trials have shown that differences in food preferences and dietary patterns are among the many life-style factors that may play a role in the inhibition of aging-associated diseases and senescence. For example, increased consumption of soybeans and their byproducts is associated with a decreased incidence of CVDs [2,3] and malignancies such as breast [4–6] and colon cancer [7–10]. A mediterranean diet and increased vegetable intake are also associated with a decreased incidence of lifestyle-related diseases, such as CVDs [11–13] and breast and colon cancer [14–17]. These findings indicate that ingredients contained in these foods may play an important role in the inhibition of aging-associated pathologies.
Inflammation and the resulting increase in oxidative stress have been shown to contribute to most, if not all, aging-associated chronic diseases [18]. Moreover, aging itself is associated with a proinflammatory status, e.g., immune system dysregulation leading to chronic mild inflammation and sustained oxidative stress [19,20]. Chronic, low-level elevation of proinflammatory cytokines and chemokines, and the resulting increases in inflammatory biomarkers, are associated with age-related declines in function as well as increased risks of morbidity and mortality [21]. Based on this background, substances contained in foods that inhibit or counteract the aging-associated proinflammatory status and decrease resulting increases in oxidative stress (i.e., chemicals that inhibit the transfer of electrons from a substance to an oxidizing agent) have attracted scientists’ interest.

Among these substances, antioxidant polyphenols are considered to be important candidates for extending healthy lifespans. Examples include isoflavones, found at high levels in soybeans, and resveratrol, which is prevalent in the Mediterranean diet. The molecules have many biological activities that may counteract the pathogenesis of aging-associated pathologies [22–24]. For example, they have anti-oxidant and anti-inflammatory properties and protect cells and genes from harmful stimuli. Early animal experiments and research performed under specific conditions or in particular animals demonstrated that the increased intake of polyphenols extended lifespans [25,26]. However, the evidence from human intervention studies as well as recent animal experiments is limited, mostly inconsistent, and inconclusive, because many studies have failed to show any effects on the prevention of aging-associated pathologies and the extension of lifespan [23,27–33]. In addition, vitamin E and β-carotene, two anti-oxidant vitamins with potent anti-oxidant properties, increased rather than decreased the incidence of CVDs and their related mortality [34–42].

Chronic inflammation has been shown to be closely associated with aging-associated pathologies, and interestingly, each of these is strongly correlated with epigenetic alteration [43,44]. There is growing evidence that epigenetic mechanisms may underlie the development of aging-associated chronic diseases and may mediate the effects of nutrition. Among the factors involved in epigenetic modifications, the roles of nutrients and their metabolites on gene methylation have gathered increasing attention because methyl group donors and related molecules that contribute to gene methylation are derived from food. We have shown that aliphatic polyamines contained in foods reduce the proinflammatory status and regulate enzymatic activities involved in gene methylation and the methylation status of the entire genome [19,45]. Furthermore, experiments showed that mouse lifespans were increased by the life-time consumption of chow containing synthetic polyamines with an overall polyamine concentration of about 3 times that in soybeans [46]. Moreover, when mice with no baseline elevated risk of carcinogenesis or prior treatment with carcinogenic stimuli were fed chows with different polyamine concentrations, and then multiple, moderate doses of a carcinogen were administered, mice that were fed high-polyamine chow had a significantly lower incidence of colon tumors (mostly cancer) [47]. The current review will discuss the relation between DNA methylation and various nutrients, as well as the mechanism by which dietary polyamines affect DNA methylation and inhibit aging-associated pathologies.

2. Aging-Associated Changes and Immunosenescence

During the aging of an organism, there is a gradual decline of normal physiological functions. In humans, aging is associated with increased susceptibility to pathological conditions such as CVDs, sarcopenia, metabolic syndrome/diabetes, decreased kidney function, anemia, neurodegenerative diseases, cancer, and physical function impairment. The biological background of aging-associated increases in these pathologies has not yet been fully elucidated, however, it is known that environmental factors play an important role. For example, differences in aging-associated pathological changes are observed even in monozygotic twins who share the same genes.

“Inflamm-aging” is a term coined to express the close relationship between chronic inflammation and aging. Immune cells are activated when they recognize substances to be eliminated, and inflammation is generally the result of immune cell activation to eliminate harmful pathogens. A first step in
this process is the binding of lymphocyte function-associated antigen 1 (LFA-1) on immune cell membranes to intercellular adhesion molecules on endothelial cells lining the innermost layer of blood vessels. The activation of immune cells results in the production of various chemical substances, including proinflammatory cytokines. Changes in immune function that are observed in the elderly are characterized by the aging-associated increase in LFA-1 expression [48–51], by shifts of immune cells and cytokine profile [52,53], and by defective humoral immunity [54]. These alterations are accompanied by progressive increases in the blood levels of proinflammatory mediators, including tumor necrosis factor α, interleukin-1, and interleukin-6 [55–58]. All three of these cytokines regulate insulin-like growth factor-1 [59], induce insulin resistance [60], inhibit erythropoiesis [61], and promote vascular dysfunction [62] and muscle wasting [63]. Their gradual increase is presumably the result of continuous stimulation by originally nonstimulatory degraded cells and other body substances [64,65].

Differences in aging-associated pathologies observed between monozygotic twins may be due to environmentally induced variations in the amounts these stimulatory materials and in the difference of immune cell response. The aging-associated pathological processes indicate the importance of reducing the aging-associated increases of substances in the body that stimulate immune cell activation, and of suppressing this activation so as to counteract the progression of aging-associated pathologies.

3. Polyamines

Polyamines are organic compounds that each have multiple amino groups (-NH$_2$). Representative polyamines include spermidine and spermine, with three and four amino groups, respectively, and molecular weights of approximately 200 and 140 g/mol, respectively. Putrescine, a precursor of polyamine, has two amines and is therefore referred to as a diamine; its biological activities differ from those of polyamines. For example, whereas spermine and spermidine have anti-inflammatory activities and are absorbed quickly from the intestinal lumen, putrescine has minimal anti-inflammatory effects and is degraded in the intestinal lumen.

Figure 1 shows the pathway of polyamine metabolism and catabolism as well as polyamine transport. Polyamines are synthesized from arginine within cells. The activities of enzymes involved in polyamine synthesis, especially ornithine decarboxylase (ODC), decrease with aging [66,67]. ODC, a rate-limiting enzyme for polyamine synthesis, has a short half-life, and can be stimulated by various factors [66,68]. It is inhibited by antizyme, which in turn inhibited by an antizyme inhibitor. Although the properties of spermidine synthase and spermine synthase have not been fully clarified, they are considered to lack a regulatory or rate-limiting role in polyamine synthesis. The administration of arginine or ornithine stimulates putrescine levels; however, the subsequent synthesis of polyamines is not necessarily stimulated in elderly people or aged animals [67,69–71]. These findings indicate that the activities of spermine and spermidine synthases decrease gradually with aging. Animal tissue exhibits an aging-associated decline in ODC activity, as well as a fall in polyamine concentration [72,73].

Spermidine synthase and spermine synthase are constitutively expressed aminopropyltransferases that catalyze the transfer of the aminopropyl group from decarboxylated S-adenosylmethionine (dcSAM) to putrescine and spermidine to form spermidine and spermine, respectively. dcSAM is converted from S-adenosylmethionine (SAM) by the enzymatic activities of adenosylmethionine decarboxylase (AdoMetDC). Intracellular spermine and spermidine are degraded by spermidine/spermine N$^1$-acetyltransferase (SSAT) and N$^1$-acetylpolyamine oxidase (APAO). SSAT, a highly inducible enzyme, catalyzes the transfer of acetyl groups from acetyl-coenzyme A to the terminal amines of spermine and spermidine. APAO preferentially catalyzes the oxidation of the N$^1$-acetylspermine and N$^1$-acetylsperrmidine produced by SSAT activity and yields spermidine and putrescine with release of an aldehyde and hydrogen peroxide. In addition to de novo synthesis, cells can take up polyamine from the extracellular space through a polyamine transporter in the cell membrane.
Figure 1. Polyamine synthesis, degradation, and transport. T-bar indicates the inhibitory activity. Arrow indicates the metabolic pathway or flow of substances. Dashed arrow indicates the supply of aminopropyl group from dcSAM. ODC: ornithine decarboxylase; SSAT: spermidine/spermine N\(^1\)-acetyltransferase; APAO: N\(^1\)-acetylpolypamine oxidase.

Polyamines, though not putrescine, suppress the production of proinflammatory cytokines from immune cells upon stimulation with lipopolysaccharide and phorbol 12-myristate 13-acetate [74]. In addition, polyamines decrease the amount of LFA-1 on the cell membrane of immune cells [19]. The anti-inflammatory properties of polyamines are not accompanied by a decreased cellular activity. Increases in polyamine concentrations enhance the blastogenic response of immune cells to mitogens such as phytohemagglutinin and concanavalinA in vitro [19]. A very interesting finding was that in the elderly, the blastogenic response of lymphocytes to mitogens is low and the amount of LFA-1 on immune cells is high [48,51,55,75]. In addition, we have found that polyamine supplementation inhibits time-dependent decreases in the natural killer activity of immune cells obtained from peripheral blood and subsequently cultured [76]; other investigators reported that polyamines extended the duration of cultured cell activity [77].

4. Source of Body Polyamines

In cancer patients, extracellular polyamines have a significant effect on intracellular polyamine concentrations. Polyamine biosynthesis is up-regulated in actively growing cells, including cancer cells, and therefore, polyamine concentrations (especially spermidine concentrations) and gene expressions and activities of enzymes involved in polyamine biosynthesis are higher in cancer tissues than in normal surrounding tissues [78–82]. Circulating blood cells also take up polyamines synthesized in cancer cells; as a result, the blood cell concentrations and urinary excretion of polyamines, especially those of spermidine, are increased in cancer patients [78,83]. These levels decrease after tumor eradication and increase after relapse, indicating that polyamines synthesized by cancer tissues are transferred to blood cells [78].

The ability to synthesize polyamines decreases with aging. However, when polyamine concentrations in blood cells are measured in healthy human adults, the aging-associated decline in polyamine concentrations is not remarkable, and large inter-individual differences are found [19,84]. Polyamines exist in almost all living organisms, and thus, foods that are comprised of various
types of organisms and their related substances contain polyamines, though at a wide variety of concentrations [85–88]. In healthy human adults, the major sources of polyamines are thought to be foods and synthesis by intestinal microbiota. Polyamines in the intestinal tract are absorbed quickly, rapidly increasing portal vein concentrations [89], and are distributed to all organs and tissues [90,91]. The exact biological mechanisms underlying the large inter-individual differences in blood polyamine concentrations in humans are not known, however, one factor is thought to be differences in the amount of polyamines supplied from the intestinal lumen, which may reflect varying preferences for foods containing polyamines. Inter-individual differences in the intestinal environment are also likely to affect polyamine synthesis possibly due to varying compositions of the intestinal bacterial flora. In fact, suppression of the polyamine supply from both foods and the intestinal microbiota results in decreased blood polyamine concentrations [92–94]. Conversely, a long-term increase in the polyamine supply from food gradually increases blood polyamine levels, especially spermine levels, in humans and mice [46,95]. However, such increases are not observed following short-term increases in polyamine intake; changes in diet for at least several months are required [46,95,96]. The absence of acute changes in blood polyamine levels may be due to homeostasis mechanisms that inhibit rapid alterations in intracellular polyamine concentrations.

In our latest study, in which volunteers were asked to eat fermented soybeans containing high levels of polyamines for a year, blood spermine levels gradually rose and were significantly higher than in the control group [97]. However, blood spermidine concentrations did not change, and those in the intervention group were similar to those in the control group throughout the study. Similar results were obtained in our previous animal studies and in a preliminary human trial [46,47,95]. In in vitro studies, we and others confirmed that interventions resulting in about 1.2-fold increases in spermine concentrations resulted in significant biological activity [19,98]. In our experiments, intracellular concentrations of spermidine had to increase two- to three-fold in human mononuclear blood cells to elicit apparent biological activities, i.e., suppression of LFA-1 expression and the production of proinflammatory cytokines. Among healthy volunteers, blood spermine levels inversely correlated with LFA-1 expression, while blood spermidine levels had no correlation with LFA-1 expression [19,97]. In one study involving an animal model, increased spermidine levels resulting from polyamine intake elicited favorable effects on cardiovascular physiology by activating autophagy [99]. However, increased polyamine intake by mice and humans did not increase spermidine levels in our repeated experiments in humans and mice, and many previous studies have shown that substances other than spermidine that can activate autophagy [100–104] did not necessarily extend lifespan or prevent CVDs [23,27–33]. Moreover, a study reported that in volunteers over age 90 the proportion of spermine relative to total polyamines was significantly higher than in individuals from age 60 to 80 [105]. The effects of increased polyamine intake on blood polyamine concentrations and the impact of biological activity of spermidine on physiological changes should be confirmed by other investigators.

5. Dietary Polyamines

All foods contain polyamines, though at widely varying levels. Therefore, personal food preferences and regional dietary patterns may greatly affect polyamine intake from food. Germ and bran, legumes such as soybeans, vegetables, and shellfish are foods with high polyamine concentrations per calorie [85–88]. The polyamine concentration in a particular food may differ depending on the part of the food examined [88,106]. For example, although fish and shellfish are lower in polyamines than beans and vegetables, higher concentrations of polyamines are found in the internal organs and roe of the fish and shellfish.

We also examined the relationship between polyamine content and dietary pattern using the food supply database of 49 Western countries from the Food and Agriculture Organization of the United Nations. The study was an ecological investigation, and the data used do not indicate the amount of foods actually consumed, however, the food supply must reflect the food demand, and thus,
we examined the following relationships: the calories of specific supplied foods relative to the total calories of all supplied foods, and the amount of polyamines contained in specific supplied foods relative to the total calories in all supplied foods. This analysis of relative amounts may reflect the food preferences of the people in each country. The results of the study indicated that the Mediterranean diet was associated with an increased amount of polyamines on a per calorie basis [1,107]. A very interesting finding was that although olive oil and wine, two components of the Mediterranean diet, do not contain any polyamines, the people who preferred these foods also preferred foods rich in polyamines per calorie [107]. In contrast, people who preferred animal fat to olive oil and those who preferred spirits and beer to wine preferred foods with low polyamine concentrations [107]. In addition, people who preferred cheese (which is sometimes related to a healthy and long lifespan) also preferred foods with low polyamine concentrations [107]. Polyamine-rich foods such as legumes, unpolished flour, vegetables, fish, and shellfish have been noted as foods relevant to a healthy long life.

Because polyamine metabolism is strictly regulated, short-term increases in polyamine intake cannot increase polyamine levels in blood cells. The finding that only long-term increases in polyamine intake can raise spermine levels in blood cells indicates that the presence of a long-lasting polyamine supply from the intestinal lumen can alter intracellular polyamine homeostasis. Changes in polyamine metabolism may affect several substances and enzymatic activities. Elevated intracellular spermine concentrations resulting from increased polyamine intake inhibits AdoMetDC activities as well as ODC, resulting in increased SAM and decreased dcSAM concentrations [108]. The increased availability of SAM enhances the activity of the methylation catalyzing enzyme DNA methyltransferase (DNMT) [109,110], and dcSAM acts to inhibit DNMT activities. These findings indicate that while polyamines have anti-oxidant and anti-inflammatory effects and protect genes and cells against harmful stimuli (Table 1), they may also affect gene methylation.

Table 1. Biological activity of polyamines.

| Activity                        | Authors                          | Journal (Year)          |
|---------------------------------|----------------------------------|-------------------------|
| Anti-inflammation                | Lovaas E. et al.                 | Free. Radic. Biol. Med. 1991, 11, 455–461. [111] |
|                                 | Zhang M. et al.                  | J. Exp. Med. 1997, 185, 1759–1768. [74] |
|                                 | Soda K. et al.                   | J. Immunol. 2005, 175, 237–245. [19] |
|                                 | Laskshetty C.V. et al.           | Indian. J. Pharmacol. 2008, 40, 121–125. [112] |
|                                 | Choi Y.H. et al.                 | J. Biomed. Sci. 2012, 19, 31. [113] |
|                                 | Paul S. et al.                   | Inflamm. Res. 2013, 62, 681–688. [114] |
|                                 | Zhou S. et al.                   | Front. Immunol. 2018, 9, 948. [115] |
| Anti-oxidant & Free radical scavenger | Tadolini B. et al.               | Biochem. Biophys. Res. Commun. 1984, 122, 550–555. [116] |
|                                 | Lovaas E. et al.                 | Free. Radic. Biol. Med. 1991, 11, 455–461. [111] |
|                                 | Khan A.U. et al.                 | Proc. Natl. Acad. Sci. USA 1992, 89, 11428–11430. [117] |
|                                 | Goss S.P. et al.                 | Chem. Res. Toxicol. 1995, 8, 800–806. [118] |
|                                 | Marzabadi M.R. et al.            | Free. Radic. Biol. Med. 1996, 21, 375–381. [119] |
|                                 | Farbiszewski R. et al.           | Neurochem. Res. 1996, 21, 1497–1503. [120] |
|                                 | Ha H.C. et al.                   | Proc. Natl. Acad. Sci. USA 1998, 95, 11140–11145. [121] |
|                                 | Jung I.L. et al.                 | Arch. Biochem. Biophys. 2003, 418, 125–132. [122] |
|                                 | Chattopadhyay M.K. et al.        | Proc. Natl. Acad. Sci. USA 2003, 100, 2261–2265. [123] |
|                                 | Belle N.A. et al.                | Brain Res. 2004, 1008, 245–251. [124] |
|                                 | Gaboriau F. et al.               | Redox. Rep. 2005, 10, 9–18. [125] |
|                                 | Fujisawa S. et al.               | Anticancer Res. 2005, 25, 965–969. [126] |
|                                 | Sava I.G. et al.                 | Free Radic. Biol. Med. 2006, 41, 1272–1281. [127] |
|                                 | Rider J.E. et al.                | Amino. Acids 2007, 33, 231–240. [128] |
|                                 | Nayvelt I. et al.                | Biomacromolecules 2010, 11, 97–105. [129] |
|                                 | Jeong J.W. et al.                | Biomol. Ther. (Seoul) 2018, 26, 146–156. [130] |
6. Epigenetics and Aging

A gene may be considered to be an “advanced source of digital information” comprised of combinations of four bases: adenine, guanine, thymine, and cytosine. One mechanism for regulating gene expression is DNA methylation, which is a change that involves only cytosine and creates gene information by adding a methyl group from SAM to cytosine residues at the C-5 position to yield 5-methylcytosine. Upstream of the gene, there is a direct repeat of cytosine and guanine called a CpG island. A CpG island is a site of transcription initiation, and in mammals, methylated cytosine within the island. A CpG island is a site of transcription initiation, and in mammals, methylated cytosine within the island.

A growing number of recent studies have shown a close relationship between aging and gene methylation [164,165]. Aging is associated with enhanced demethylation of DNA in various organs and tissues in several animals and humans [166–168]. However, increased methylation associated with age has also been reported in some genes [169,170]. Generally, aberrant methylation status (both increases and decreased) that is associated with aging is accompanied by decreased activity of DNMT [168,171–175], involved in the regulation of gene methylation.

Aging-associated changes in DNA methylation status indicate that DNA methylation is susceptible to environmental stimuli. One of the most typical examples is the aging-associated differences between homozygotic twins. These twins share the same genes and they developed in the same environment.

Table 1. Cont.

| Activity | Authors | Journal (Year) |
|----------|---------|----------------|
| Radioprotection | Coudri A. et al. | Int. J. Cancer 1986, 38, 103–107. [131] |
| | Arundel C.M. et al. | Radiat. Res. 1988, 114, 634–640. [132] |
| | Held K.D. et al. | Int. J. Radiat. Biol. 1991, 59, 699–710. [133] |
| | Snyder R.D. et al. | Radiat. Res. 1994, 137, 67–75. [134] |
| | Williams J.R. et al. | Biochem. Biophys. Res. Commun. 1994, 201, 1–7. [135] |
| | Spotheim-Maurizot M. et al. | Int. J. Radiat. Biol. 1995, 68, 571–577. [136] |
| | Newton G.L. et al. | Radiat. Res. 1996, 145, 776–780. [137] |
| | Chiu S. et al. | Radiat. Res. 1998, 149, 543–549. [138] |
| | Sy D. et al. | Int. J. Radiat. Biol. 1999, 75, 953–961. [139] |
| | Warters R.L. et al. | Radiat. Res. 1999, 151, 354–362. [140] |
| | Douki T. et al. | Radiat. Res. 2000, 153, 29–35. [141] |
| | von Deutsch A.W. et al. | Gravit. Space Biol. Bull. 2005, 18, 109–110. [142] |
| Protection from ultraviolet light | Snyder R.D. et al. | Photochem. Photobiol. 1990, 52, 525–532. [143] |
| | Williams J.R. et al. | Biochem. Biophys. Res. Commun. 1994, 201, 1–7. [144] |
| | Pothipongsa A. et al. | Appl. Biochem. Biotechnol. 2012, 168, 1476–1488. [145] |
| Protection from chemicals & other stress | Rajalakshmi S. et al. | Biochemistry. 1978, 17, 4515–4518. [146] |
| | Mackintosh C.A. et al. | Biochem. J. 2000, 351, 439–447. [147] |
| | Di Mascio P. et al. | Arch. Biochem. Biophys. 2000, 373, 368–374. [147] |
| | Chauhan S.D. et al. | FASEB J. 2003, 17, 773–775. [148] |
| | Guggliucci A. et al. | Life Sci. 2003, 72, 2603–2616. [149] |
| | Sagor G.H. et al. | Transgenic Res. 2013, 22, 995–605. [150] |
| | Okumura S. et al. | Liver Transpl. 2016, 22, 1251–1244. [151] |
However, a considerable difference in DNA methylation pattern is observed in aged twins in comparison with young twins [176,177]. Many environmental factors have been shown to affect DNA methylation status. Various types of cellular stress seem to affect epigenetic alterations that may lead to deleterious consequences. Exposure to fine particle air pollution affects DNA methylation status in blood cells [178–183] and placenta [184]. Cigarette smoking has adverse effects on health and is associated with changes in epigenetic marks. Prenatal smoke exposure affects DNA methylation in blood cells from children of smoking mothers [185,186]. Smoking may induce DNA methylation alterations in cells of both the innate and adaptive immune systems [187]. Epigenetic alterations caused by chronic cigarette smoke sensitize bronchial epithelial cells to malignant transformation [188–190]. Smoking-associated changes in methylation are observed in genes related to the progression of CVDs [190,191] and the age acceleration [192–194]. Alcohol consumption is associated with alcohol-related DNA methylation changes in blood cells [195], and DNA methylation alterations in offspring are associated with maternal alcohol consumption [196]. Exercise alters epigenetic marks in human skeletal muscle and adipose tissue [197–200], and nutritional habits change the methylation status of the promoter area [201]. The effect of exercise on improved cardiorespiratory fitness and running performance is accompanied by widespread demethylation of CpG islands, which is the opposite of the methylation changes observed during aging [197,199]. Additionally, interventions that extended rodent lifespan inhibited age-associated changes in DNA methylation [202–204]. Therefore, differences in exposure to these and other environmental factors are expected to affect methylation status in homozygotic twins, resulting in differences in health conditions [205–207].

Alteration of methylation status with aging changes chromatin accessibility, resulting in aberrant gene transcription, as well as genomic instability. These factors may be key regulators of the aging process and contributors to the development of aging-associated diseases [208–214], including neoplastic growth [189,215–219] and aging itself [220–223]. For example, when methylation arises in the CpG islands encoding genes that suppress aging-associated disease(s) and/or when demethylation arises in the CpG islands encoding genes that cause aging-associated disease(s), the onset and the progression of aging-associated disease(s) are accelerated. Recently, aging-associated changes in multiple CpG sites across the genome in blood cells were shown to accurately predict the biological ages of individuals, independent of their chronological ages, and also predicted all-cause mortality [210,216,224–227]. This epigenetic status has been shown to be a potential biomarker of aging in humans and is associated with several aging-associated disease phenotypes [225,226,228–230].

7. Nutrients and Their Metabolites and Enzymes Related to DNA Methylation

The methylation of DNA is regulated by DNMTs (especially DNMT1, DNMT3a, and DNMT3b) in the presence of SAM, which is the methyl group donor for methylation of cytosine residues at the C-5 position that yields 5-methylcytosine. SAM, another substrate for polyamine synthesis, is converted from methionine and adenosine triphosphate (ATP) by methionine adenosyltranferase. Methionine is an essential amino acid in humans and is used in protein biosynthesis. SAM serves as a methyl group donor in many methyltransferase reactions, including DNA methylation, and is converted to S-adenosyl-L-homocysteine (SAH). SAH is a potent inhibitor of DNMT(s), especially DNMT1 [231–233], and is quickly hydrolyzed and converted to homocysteine and adenosine by adenosylhomocysteínase. Homocysteine can be recycled into methionine or converted into cysteine. Homocysteine is converted to methionine either via methionine synthase or betaine-homocysteine methyltransferase [234]. Methionine synthase requires vitamin B12 as a co-factor to transfer a methyl group from methyltetrahydrofolate to homocysteine to form S-methionine. Betaine homocysteine methyltransferase transfers a methyl group from betaine to form S-methionine. Interconversion of homocysteine and cysteine, through the intermediate cystathionine, is called the transsulfuration pathway. Cystathionine β-synthase catalyzes the conversion of homocysteine to cystathionine and water. Cystathionine is then converted to cysteine by the enzymatic activity of cystathionine γ-lyase. Vitamin B6 is required as co-enzyme by both cystathionine β-synthase and cystathionine γ-lyase.
SAM and putrescine are substrates for polyamine synthesis. An aminopropyl group is supplied by dcSAM for the synthesis of spermidine and spermine. dcSAM is converted from SAM by the enzymatic activity of AdoMetDC. dcSAM, which donates an aminopropyl group for polyamine synthesis, is a strong inhibitor of DNMT [235]. dcSAM is converted to methylthioadenosine (MTA) after donation of an aminopropyl group for polyamine synthesis. MTA is metabolized solely by MTA-phosphorylase to yield 5-methylthioribose-1-phosphate and adenine, a crucial step in the methionine and purine salvage pathways, respectively.

In humans, arginine is a semi-essential or conditionally essential amino acid, especially during the growth period. Arginine occurs at high concentrations in meats, nuts, legumes, and seafood, among others. L-ornithine, converted from L-arginine, is a non-proteinogenic amino acid that plays a role in the urea cycle and is contained in foods such as legumes and seafood. Foods with high levels of putrescine, spermidine, and spermine are described in the “dietary polyamines” section. Methionine, a substrate for SAM, is an essential amino acid and is abundant in vegetables, fruits, legumes, nuts, and meat. Homocysteine is a non-proteinogenic α-amino acid and can be recycled into methionine or converted into the amino acid cysteine with the aid of vitamin B6, vitamin B12, folate, and others. Cysteine is a semi-essential proteinogenic amino acid. Betaine participates in the conversion from homocysteine to methionine as a methyl group donor, and is contained in several foods. These facts suggest that diet has great impact on DNA methylation, and this has been proven in experimental studies. For example, high-fat, low-protein, or energy-restricted diets have been shown to be associated with and alter epigenetic marks [202,204,236–240].

When considering the metabolic pathway, there are two targets by which nutritional and dietary factors specifically affect DNA methylation: (1) changing the availability of methyl donors, and (2) altering the activity of DNMT by altering the concentrations of substances that inhibit DNMT.

### 7.1. Changing the Availability of Methyl Donors

Recent investigations have focused on one-carbon metabolism because many dietary ingredients are involved in this metabolic pathway. Specific targets to increase the availability of methyl donor include acceleration of the conversion from homocysteine to methionine. Abnormally high levels of homocysteine have been reported to be a significant risk factor for the development of a wide range of diseases such as in cerebrovascular diseases [241–244], various CVDs [245–249], cognitive impairment including Alzheimer’s disease [250–252], fractures [253–255], and mortality [256]. Deficiencies of vitamin B12, folate, or vitamin B6 seem to play an important role in the occurrence of hyperhomocysteinemia, because they are essential for homocysteine metabolism (Figure 2), and treatment with B-vitamin supplementation (B6, B12, and folate) has been demonstrated to effectively lower homocysteine levels [257–261]. The majority of these trials have focused on the prevention of pathological changes associated with vascular dysfunction, because folic acid prevents homocysteine-induced proinflammatory status and apoptosis of endothelial cells [248,262]. A high level of homocysteine in the blood seems to provoke endothelial cell injury; this leads to inflammation in the blood vessels and accelerates atherogenesis, which can result in ischemic injury. Several studies of homocysteine-lowering treatments have shown a favorable effect on vascular pathologies associated with hyperhomocysteinemia [257,263,264]. However, other studies and meta-analyses have demonstrated that lowering homocysteine using B vitamins had no significant effect on stroke prevention [260,261,265,266], prevention of myocardial infarction [260,261,266–270], individual or global cognitive function [271–273], or other pathological conditions [274–276].
In addition to attenuating both inflammation and endothelial cell dysfunction [262,277], lowering homocysteine levels induces changes in the availability of methyl donors by facilitating the conversion from homocysteine to methionine, which may help regulate DNA methylation status [264,278–281]. Hyperhomocysteinemia-induced vascular pathologies, such as atherosclerosis, inflammation, hypertension, and diabetes, are also associated with alteration of DNA methylation status [282–287]. The failure of many trials of homocysteine-reducing treatments for the prevention of aging-associated diseases indicates that the alteration of methyl group availability is not sufficient to alter DNA methylation status, and thereby suppress the progression of aging-associated pathologies [288–290]. Similar findings have been reported in trials examining the ability of resveratrol to reduce homocysteine levels. Resveratrol significantly decreased serum levels of homocysteine in rats on a methionine-rich diet [291,292], and preferentially affected the methylation status of cancer cells [292–294]. However, despite extensive trials, resveratrol failed to inhibit aging-associated pathologies or extend the lifespan in mammals [27–33].

Based on the theoretical background of homocysteine-reducing treatment, an alternative means of affecting the availability of methyl groups is to change the amount of methionine and/or SAM intake. However, methionine supplementation in the diet specifically increases mitochondrial radical oxygen species production and mitochondrial DNA oxidative damage [277,295–297]. Furthermore, these biological activities of methionine provoke many deleterious effects [298–300]. These biological activities seem to be due to excess methionine or SAM. Although it is unknown what net effect increasing the number of methyl groups has on DNA methylation, supplementation with either methionine or SAM affects the DNA methylation status [162,298,301–304].

Conversely, methionine restriction has been shown to successfully decrease the production of mitochondrial reactive oxygen species, reduce free radical leakage, and decrease oxidative damage to mitochondrial DNA [305–308]. Furthermore, the restriction of methyl groups in foods alters DNA methylation status. Several experiments have shown that deficiency of methyl groups enhances demethylation of the entire genome and of several genes [309,310]. Other studies have shown that methionine restriction for a limited period of time, though not for long periods, affects global DNA methylation [311], inhibits chemically-induced neoplastic growth [312], and extends the lifespan of various organisms, including mammals [311,313–315]. One very interesting finding is that old animals fed a methionine-restricted diet demonstrated a gene methylation status similar to that of young rats [309]. These findings indicate that an important mechanism of lifespan prolongation by methionine restriction involves changes of global DNA methylation status.

7.2. Altering DNA Methyltransferase (DNMT) Activity

Chronic elevation in homocysteine levels results in parallel increases in SAH [316]. SAH binds with high affinity to the catalytic region of most SAM-dependent methyltransferases [233,317], enabling it to
act a potent inhibitor of DNMT(s) [231,232]. The ratio of SAM to SAH, referred to as the “methylation index” has been suggested as an indicator of methylating capacity. Increased homocysteine and a low SAM/SAH ratio in plasma, both of which may reflect reduced transmethylation reactions and the resulting alteration of DNA methylation status, may be responsible for the pathogenesis of several disorders, especially angiopathy [318–320]. In contrast, the failure of successful vitamin treatment of hyperhomocysteinemia to decrease vascular events may be due to a weak inhibitory effect of SAH on DNMT or to the fact that vitamin treatment cannot decrease SAH levels for long enough to induce changes in the methylome and thereby prevent aging-associated pathologies.

The activity of DNMT is closely associated with the concentration of dcSAM, which is converted from SAM by the enzymatic activity of AdoMetDC, and with the dcSAM to SAM ratio [235,321]. An increase in dcSAM inhibits DNMT [321,322]. Therefore, while SAM availability regulates DNA methylation, the modulation of dcSAM activity does so more directly. Intracellular concentrations of dcSAM rise in cells in which polyamine concentrations are decreased due to several factors: decreased polyamine synthesis; overexpression of antizyme, which degrades ODC; or treatment with α-D,L-difluoromethylornithine hydrochloride (DFMO), which inhibits ODC activities [235,321,323,324]. Simultaneously, an increase in dcSAM induced by inhibition of ODC activity has been shown to decrease DNMT by decreasing DNMT protein levels and inducing hypomethylation of the whole genome [321,322,325].

Our latest study showed that ODC inhibition by DFMO increased dcSAM concentrations and the dcSAM/SAM ratio, and decreased activities of DNMT 1, 3a, and 3b in Jurkat cells. However, increased dcSAM concentrations did not change DNMT protein levels. In addition to ODC inhibition, spermine supplementation inhibited AdoMetDC activity and decreased dcSAM concentrations with a decreased dcSAM/SAM ratio, as well as re-activated DNMT 3a and 3b. However, DNMT 1 was not re-activated by spermine supplementation. Decreases in AdoMetDC activity and dcSAM concentrations were also achieved when Jurkat cells were supplemented with spermine alone. Similarly, changing the availability of methyl donors has been shown to affect DNMT3a and 3b expressions [326]. A methylation microarray was used to analyze the effects of DFMO and spermine on the methylation status of the entire genome. The restriction enzyme NotI cleaves a specific DNA sequence, however, when cytosine in the sequence is methylated, this cleavage fails. Microarray analyses of the methylome at the site of NotI cleavage showed that increased dcSAM with decreased polyamine concentrations were associated with aberrant methylation of the entire genome. Depending on the portion of the genome, the decline in DNMT activity not only induced increases in genome demethylation but also reinforced the methylation at other locations. In other words, polyamine deficiency both increased demethylation in certain areas and increased methylation in other areas [45,47]. Conversely, decreases in dcSAM concentrations induced by spermine supplementation were associated with suppression of aberrant methylation induced by ODC inhibition (Figure 3).
Figure 3. The effects of decreased ODC activity and spermine supplementation. (a) Decreased ODC activity increases decarboxylated S-adenosylmethionine (dcSAM) concentrations, because the aminopropyl group from dcSAM is not required for polyamine synthesis. Increased dcSAM inhibits DNA methyltransferase (DNMT) activity, resulting in enhanced aberrant methylation of whole genome and enhanced demethylation of ITGAL (LFA-1 promoter); (b) Increased spermine from extracellular sources suppresses adenosylmethionine decarboxylase (AdoMetDC) activity due to negative feedback to maintain intracellular polyamine concentrations. Decreased dcSAM concentrations induced by decreased AdoMetDC activity results in increased DNMT activity, resulting in recovery of the ability to maintain the methylation status of the entire genome and enhancement of ITGAL methylation. T-bar indicates the inhibitory activity. Black arrow indicates the metabolic pathway or flow of substances. Brown arrow indicates the increase (upward arrow) or decrease (downward arrow) of the amount of substance or the enzymatic activity.

8. Aging, Polyamines, and DNA Methylation

Generally, aging is associated with decreases in ODC [327] and DNMT activities [174,328,329], and enhanced demethylation of the LFA-1 promoter area in association with increases in LFA-1 protein levels [19,97,330]. Decreases in DNMT activity decrease donations of methyl groups to cytosine residues, and seem to enhance genome-wide demethylation; however, DNA methylation drift seems to be a non-directional change as it involves both hypermethylation and hypomethylation events during aging [47,177,331–335]. In a murine model involving chows with different polyamine concentrations, the methylation status of the entire genome in old mice fed regular or low-polyamine chow showed an increase in aberrant methylation. However, lifelong intake of high-polyamine chow prevented aging-associated increase in aberrant methylation [47]. The regulation of methylation status by polyamine intake was very similar to that observed in our in vitro study in which DNMT suppression resulting from DFMO-induced ODC inhibition caused aberrant methylation, while spermine supplementation reversed this condition [45].

Bi-directional changes in methylation status were also observed in the promoter area of LFA-1 (called ITGAL). Detailed base sequencing after treatment with bisulfite, which converts unmethylated, though not methylated, cytosine to uracil, showed that the site responsible for LFA-1 expression in immune cells [165,336] was demethylated and associated with increased LFA-1 protein levels after ODC inhibition. However, other CpG sites in ITGAL were either demethylated or methylated in a site-specific manner. Spermine supplementation reversed spermine deficiency-induced
demethylation of the CpG area responsible for LFA-1 expression and decreased LFA-1 protein levels. Similarly, changes in the status of DFMO-induced methylation in most other areas were almost reversed by spermine supplementation. DNMT and SAM seem to act together to regulate methylation status, and defective functional activity of DNMT may fail to maintain appropriate methylation [337].

Since polyamines have many biological activities that may counteract aging-associated pathologies, and play an important role in the regulation of DNA methylation, my colleagues and I hypothesized that increased polyamine intake may reduce the incidence of conditions linked to old age. We demonstrated that lifelong consumption of polyamine-rich chow increased blood spermine levels, inhibited aging-associated pathological changes in mouse organs, inhibited aging-associated increases in LFA-1 protein levels, and extended mouse lifespans [46,47,95]. In our latest human interventional trial, increased polyamine intake for 1 year increased blood spermine levels and inhibited aging-associated increases in LFA-1 protein levels [97].

9. Possible Role of Polyamines in Inhibiting Tumorigenesis

Aging is one of the largest risk factors of carcinogenesis [338], and there is growing evidence that aging-associated changes in DNA methylation status are closely related to the occurrence of cancer [339–342]. Given the many biological activities of polyamines (Table 1) that may inhibit aging-associated pathological processes, including the progression of aberrant DNA methylation, and the experimental findings showing that increased polyamine intake extended animal lifespans, it is reasonable to assume that increased polyamine intake may suppress neoplastic diseases. To test this hypothesis, animal models were employed in which dietary patterns and carcinogen exposure were similar to those in humans. The majority of humans are born without an increased risk of tumorigenesis and grow up with a regional dietary pattern. Under such circumstances, humans are exposed to weak, though repeated carcinogenic stimuli throughout their lives. BALB/c mice were fed chows with different polyamine concentrations, and were then repeatedly administered moderate amounts of a carcinogen (20 mg/kgBW of 1,2-demethylhydrazine once a week for 12 consecutive weeks). Mice fed high-polyamine chow had a lower incidence of neoplastic growth (mostly colon cancer) [47]. Similar results were obtained by a group at Josai University, which examined enhancement of tumorigenesis by increased polyamine intake. However, in rats administered low-dose (85 mg/kgBW) 2-amino-1-methyl-6-phenylimidazole for 8 days and chows containing three different polyamine concentrations, increased polyamine intake did not increase carcinogenesis and even seemed to suppress it [343].

ODC is a focus of therapies that aim to prevent carcinogenesis because it is a transcriptional target of a proto-oncogene [344–346], and many studies have shown that transfection of the ODC gene results in increased intracellular polyamine levels and malignant transformation [347–353]. Most reports on the roles of ODC in malignant transformation have examined cells that were already at risk of tumorigenesis. In contrast, malignant transformation after transfection of the ODC gene in normal cells has not been observed [354–356]. Reaffirming the importance of ODC inhibition in tumorigenesis, increased polyamine concentration reduces ODC translation in reticulocyte lysates [357,358] and in cell cultures [359]. In cells with normal homeostasis, the influx of polyamines from the extracellular space suppresses ODC activity, with spermine being the most effective, and putrescine the least effective polyamine in regulating ODC activity [98]. One previous study reported significant suppression of ODC activity in the intestinal mucosa of rats fed chow with high polyamine concentrations [96].

In a cohort study, increased polyamine intake from food was associated with an increased number of colon polyps in patients who were already at high risk [360]. However, a study of subjects at low risk of neoplastic diseases showed that increased polyamine intake was associated with decreased tumorigenesis (colon polyps) [361]. These results are similar to those in animal studies, in which increased polyamine intake accelerated tumorigenesis in animals at high risk of tumorigenesis, while increased polyamine intake followed by repeated weak carcinogenic stimuli
decreased tumorigenesis. In addition, a polyamine-rich diet \cite{88,107} was associated with a decreased incidence of breast and colon cancer \cite{14–17}.

10. Future Perspectives

The biological activities of polyamines that may help inhibit aging-associated pathologies are summarized in Figure 4. At this point, despite extensive studies, there is no proof that changes in specific DNA methylation patterns, in a specific signal transduction pathways, or specific proteins can extend lifespans, especially in mammals \cite{213}. Instead, there is an overwhelming scientific consensus supporting the important role of epigenetic changes in aging-associated pathologies and lifespan alteration \cite{173,210,226,362–367}. Based on these perspectives, it is important to maintain levels of DNMT, which decrease with age and inhibit aging-associated aberrant DNA methylation. This requires sustained biological activity, because many environmental factors continuously interfere with the gene methylation status.

![Figure 4](image-url)

**Figure 4.** The role of spermine in the inhibition of aging-associated pathologies. Increased polyamine intake elevates spermine levels. Spermine is converted to spermidine by spermidine/spermine \(N^1\)-acetyltransferase (SSAT) and \(N^1\)-acetylpolyamine oxidase (APAO). Increased polyamines (spermine and spermidine) can protect cells and genes from harmful stimuli. Additionally, increased spermine activates the negative feedback system to inhibit the activities of ODC and AdoMetDC. ODC is a transcriptional target of a proto-oncogene, and AdoMetDC inhibits DNMT activity by increasing dcSAM concentrations, and thus, regulating the methylation status of DNA. Decreased damage of cells and genes as a result of polyamine activity inhibits aging-associated increase in originally inoffensive substances that provoke chronic immune cell activation. Spermine-induced suppression of the pro-inflammatory status observed with aging (e.g., increased production of pro-inflammatory cytokines, and increased expression of lymphocyte function-associated antigen 1 (LFA-1) on immune cells) may help inhibit the progression of aging-associated diseases. T-bar indicates the inhibitory activity. Black arrow defines the relation of upstream and downstream. Change in thickness of arrows indicates the barrier effect of polyamine from harmful stimuli.

Sustained elevations in polyamine concentrations by food intake, and the resulting changes in intracellular homeostasis, must continuously regulate the methylation status of various genes relevant to the onset and progression or the inhibition of aging-associated diseases. From the point of view of chronic inflammation, the ability of polyamines to prevent noxious stimuli from damaging genes, cells, and tissues can inhibit aging-associated increases in the production of compounds...
from originally inoffensive substances in the body. Unlike viruses, bacteria, and other pathogenic microorganisms that strongly arouse immune activation, such compounds weakly stimulate immune cell activation. In addition to the possible reduction of these compounds, spermine suppresses LFA-1 expression via regulation of gene methylation. Because inflammation is also closely associated with gene methylation [44,368–371], suppression of immune cell activation may counteract the progression of aging-associated pathologies.

The difference in the effects of spermine and those of aging on the methylation of individual genes has not been fully elucidated. In addition, the effect of spermine on DNMT levels and activity should be further investigated. In an experiment on the effects of aging and spermine on LFA-1 expression, subsets of immune cells in which expression is increased with aging seemed to be different from those in which LFA-1 is decreased by spermine [19,97]. These results indicate that spermine-induced changes in methylation status in genes and various cell types must not be the same as those induced by aging. Elucidating these differences and developing approaches to increase blood spermine levels are crucial for extending the human lifespan.

**Funding:** This research received no external funding.

**Conflicts of Interest:** The author declares no conflict of interest.

**Abbreviations**

DNMT DNA methyltransferase  
SAM  S-adenosylmethionine  
SAH  S-adenosyl-L-homocysteine  
dcSAM decarboxylated S-adenosylmethionine  
CVD cardiovascular disease  
LFA-1 lymphocyte function-associated antigen 1  
ODC ornithine decarboxylase  
AdoMetDC adenosylmethionine decarboxylase  
SSAT spermidine/spermine N\(^1\)-acetyltransferase  
APAO N\(^1\)-acetylpolyamine oxidase  
MTA methylthioadenosine  
DFMO \(\alpha\)-D,L-difluoromethylornithine hydrochloride

**References**

1. Soda, K.; Kano, Y.; Chiba, F. Food Polyamine and Cardiovascular Disease—An Epidemiological Study. *Glob. J. Health Sci.* 2012, 4, 170–178. [CrossRef] [PubMed]
2. Nagata, C.; Wada, K.; Tamura, T.; Konishi, K.; Goto, Y.; Koda, S.; Kawachi, T.; Tsuji, M.; Nakamura, K. Dietary Soy and Natto Intake and Cardiovascular Disease Mortality in Japanese Adults: The Takayama Study. *Am. J. Clin Nutr.* 2017, 105, 426–431. [CrossRef] [PubMed]
3. Erdman, J.W., Jr. Aha Science Advisory: Soy Protein and Cardiovascular Disease: A Statement for Healthcare Professionals from the Nutrition Committee of the Aha. *Circulation* 2000, 102, 2555–2559. [CrossRef] [PubMed]
4. Trock, B.J.; Hilakivi-Clarke, L.; Clarke, R. Meta-Analysis of Soy Intake and Breast Cancer Risk. *J. Natl. Cancer Inst.* 2006, 98, 459–471. [CrossRef] [PubMed]
5. Wu, A.H.; Yu, M.C.; Tseng, C.C.; Pike, M.C. Epidemiology of Soy Exposures and Breast Cancer Risk. *Br. J. Cancer* 2008, 98, 9–14. [CrossRef] [PubMed]
6. Kim, M.K.; Kim, J.H.; Nam, S.J.; Ryu, S.; Kong, G. Dietary Intake of Soy Protein and Tofu in Association with Breast Cancer Risk Based on a Case-Control Study. *Nutr. Cancer* 2008, 60, 568–576. [CrossRef] [PubMed]
7. Spector, D.; Anthony, M.; Alexander, D.; Arab, L. Soy Consumption and Colorectal Cancer. *Nutr. Cancer* 2003, 47, 1–12. [CrossRef] [PubMed]
8. Oba, S.; Nagata, C.; Shimizu, N.; Shimizu, H.; Kametani, M.; Takeyama, N.; Ohnuma, T.; Matsushita, S. Soy Product Consumption and the Risk of Colon Cancer: A Prospective Study in Takayama, Japan. *Nutr. Cancer* 2007, 57, 151–157. [CrossRef] [PubMed]
9. Yang, G.; Shu, X.O.; Li, H.; Chow, W.H.; Cai, H.; Zhang, X.; Gao, Y.T.; Zheng, W. Prospective Cohort Study of Soy Food Intake and Colorectal Cancer Risk in Women. *Am. J. Clin. Nutr.* 2009, 89, 577–583. [CrossRef] [PubMed]

10. Yan, L.; Spitznagel, E.L.; Bosland, M.C. Soy Consumption and Colorectal Cancer Risk in Humans: A Meta-Analysis. *Cancer Epidemiol. Biomarkers Prev.* 2010, 19, 148–158. [CrossRef] [PubMed]

11. Sofi, F.; Abbate, R.; Gensini, G.F.; Casini, A. Accruing Evidence on Benefits of Adherence to the Mediterranean Diet on Health: An Updated Systematic Review and Meta-Analysis. *Am. J. Clin. Nutr.* 2010, 92, 1189–1196. [CrossRef] [PubMed]

12. Estruch, R.; Ros, E.; Salas-Salvadó, J.; Covas, M.I.; Corella, D.; Arós, F.; Gómez-Gutierre, E.; Ruiz-Gutiérrez, V.; Fiol, M.; Lapetra, J.; et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. *N. Engl. J. Med.* 2018, 378, e34. [CrossRef] [PubMed]

13. Kris-Etherton, P.; Eckel, R.H.; Howard, B.V.; St Jeor, S.; Bazzarre, T.L. Nutrition Committee Population Science Committee; Clinical Science Committee of the American Heart Association. AHA Science Advisory: Lyon Diet Heart Study. Benefits of a Mediterranean-Style, National Cholesterol Education Program/American Heart Association Step I Dietary Pattern on Cardiovascular Disease. *Circulation* 2001, 103, 1823–1825. [PubMed]

14. Benetou, V.; Trichopoulou, A.; Orфанos, P.; Naska, A.; Lagiou, P.; Boffetta, P.; Trichopoulos, D.; Greek, E.C. Conformity to Traditional Mediterranean Diet and Cancer Incidence: The Greek Epic Cohort. *Br. J. Cancer* 2008, 99, 191–195. [CrossRef] [PubMed]

15. Couto, E.; Boffetta, P.; Lagiou, P.; Ferrari, P.; Buckland, G.; Overvad, K.; Dahm, C.C.; Tjønneland, A.; Olsen, A.; Clavel-Chapelon, F.; et al. Mediterranean Dietary Pattern and Cancer Risk in the Epic Cohort. *Br. J. Cancer* 2011, 104, 1493–1499. [CrossRef] [PubMed]

16. Trichopoulou, A.; Bamia, C.; Lagiou, P.; Trichopoulos, D. Conformity to Traditional Mediterranean Diet and Breast Cancer Risk in the Greek Epic (European Prospective Investigation into Cancer and Nutrition) Cohort. *Am. J. Clin. Nutr.* 2010, 92, 620–625. [CrossRef] [PubMed]

17. Fung, T.T.; Hu, F.B.; McCullough, M.L.; Newby, P.K.; Willett, W.C.; Holmes, M.D. Diet Quality Is Associated with the Risk of Estrogen Receptor-Negative Breast Cancer in Postmenopausal Women. *J. Nutr.* 2006, 136, 466–472. [CrossRef] [PubMed]

18. Stepanova, M.; Rodriguez, E.; Birerdinc, A.; Baranova, A. Age-Independent Rise of Inflammatory Scores May Contribute to Accelerated Aging in Multi-Morbidity. *Oncotarget* 2015, 6, 1414–1421. [CrossRef] [PubMed]

19. Soda, K.; Kano, Y.; Nakamura, T.; Kasono, K.; Kawakami, M.; Konishi, F. Spermine, a Natural Polyamine, Suppresses LFA-1 Expression on Human Lymphocyte. *J. Immunol.* 2005, 175, 237–245. [CrossRef] [PubMed]

20. Ferrucci, L.; Corsi, A.; Lauretani, F.; Bandinelli, S.; Bartali, B.; Taub, D.D.; Guralnik, J.M.; Longo, D.L. The Origins of Age-Related Proinflammatory State. *Blood* 2005, 105, 2294–2299. [CrossRef]

21. Franceschi, C.; Campisi, J. Chronic Inflammation (Inflammaging) and Its Potential Contribution to Age-Associated Diseases. *J. Gerontol. A Biol. Sci. Med. Sci.* 2014, 69 (Suppl. 1), S4–S9. [CrossRef]

22. Balmir, F.; Staack, R.; Jeffrey, E.; Jimenez, M.D.; Wang, L.; Potter, S.M. An extract of soy flour influences serum cholesterol and thyroid hormones in rats and hamsters. *J. Nutr.* 1996, 126, 3046–3053. [CrossRef] [PubMed]

23. Sacks, F.M.; Lichtenstein, A.; Van Horn, L.; Harris, W.; Kris-Etherton, P.; Winston, M. Soy protein, isoflavones, and cardiovascular health: An american heart association science advisory for professionals from the nutrition committee. *Circulation* 2006, 113, 1034–1044. [CrossRef] [PubMed]

24. Song, T.; Lee, S.O.; Murphy, P.A.; Hendrich, S. Soy Protein with or without Isoflavones, soy germ and soy germ extract, and daidzein lessen plasma cholesterol levels in golden syrian hamsters. *Exp. Biol. Med.* 2003, 228, 1063–1068. [CrossRef]

25. Baur, J.A.; Pearson, K.J.; Price, N.L.; Jamieson, H.A.; Lerin, C.; Kalra, A.; Prabhu, V.V.; Allard, J.S.; Lopez-Lluch, G.; Lewis, K.; et al. Resveratrol Improves Health and Survival of Mice on a High-Calorie Diet. *Nature* 2006, 444, 337–342. [CrossRef] [PubMed]

26. Mancuso, R.; del Valle, J.; Modol, L.; Martinez, A.; Granado-Serrano, A.B.; Ramírez-Nunez, O.; Pallas, M.; Portero-Otin, M.; Osta, R.; Navarro, X. Resveratrol Improves Motoneuron Function and Extends Survival in Sod1(G93a) Als Mice. *Neurotherapeutics* 2014, 11, 419–432. [PubMed]

27. Pearson, K.J.; Baur, J.A.; Lewis, K.N.; Peshkin, L.; Price, N.L.; Labinskyy, N.; Swindell, W.R.; Kamara, D.; Minor, R.K.; Perez, E.; et al. Resveratrol Delays Age-Related Deterioration and Mimics Transcriptional Aspects of Dietary Restriction without Extending Life Span. *Cell Metab.* 2008, 8, 157–168. [CrossRef] [PubMed]
28. Miller, R.A.; Harrison, D.E.; Astle, C.M.; Baur, J.A.; Boyd, A.R.; de Cabo, R.; Fernandez, E.; Flurkey, K.; Javors, M.A.; Nelson, J.F.; et al. Rapamycin, but Not Resveratrol or Simvastatin, Extends Life Span of Genetically Heterogeneous Mice. *J. Gerontol. A Biol. Sci. Med. Sci.* 2011, 66, 191–201. [CrossRef] [PubMed]

29. Staats, S.; Wagner, A.E.; Kowalewski, B.; Rieck, F.T.; Soukup, S.T.; Kulling, S.E.; Rimbach, G. Dietary Resveratrol Does Not Affect Life Span, Body Composition, Stress Response, and Longevity-Related Gene Expression in Drosophila Melanogaster. *Int. J. Mol. Sci.* 2018, 19, 223. [CrossRef] [PubMed]

30. Johnson, A.A.; Riehle, M.A. Resveratrol Fails to Extend Life Span in the Mosquito Anopheles Stephensi. *Rejuvenation Res.* 2015, 18, 473–478. [CrossRef] [PubMed]

31. Kaeberlein, M.; McDonagh, T.; Heltweg, B.; Hixon, J.; Westman, E.A.; Caldwell, S.D.; Napper, A.; Curtis, R.; DiStefano, P.S.; Fields, S.; et al. Substrate-Specific Activation of Sirtuins by Resveratrol. *J. Biol. Chem.* 2005, 280, 17038–17045. [CrossRef] [PubMed]

32. Burnett, C.; Valentini, S.; Cabreiro, F.; Goss, M.; Somogyvari, M.; Piper, M.D.; Hoddinott, M.; Sutphin, G.L.; Leko, V.; McElwee, J.J.; et al. Absence of Effects of Sir2 Overexpression on Lifespan in C. Elegans and Drosophila. *Nature* 2011, 477, 482–485. [CrossRef] [PubMed]

33. Strong, R.; Miller, R.A.; Astle, C.M.; Baur, J.A.; de Cabo, R.; Fernandez, E.; Guo, W.; Javors, M.; Kirkland, J.L.; Nelson, J.F.; et al. Evaluation of Resveratrol, Green Tea Extract, Curcumin, OXaloacetic Acid, and Medium-Chain Triglyceride Oil on Life Span of Genetically Heterogeneous Mice. *J. Gerontol. A Biol. Sci. Med. Sci.* 2013, 68, 6–16. [CrossRef] [PubMed]

34. Ernst, I.M.; Pallauf, K.; Bendall, J.K.; Paulsen, L.; Nikolai, S.; Huebbe, P.; Roeder, T.; Rimbach, G. Vitamin E Supplementation and Lifespan in Model Organisms. *Ageing Res. Rev.* 2013, 12, 365–375. [CrossRef] [PubMed]

35. Cook, N.R.; Albert, C.M.; Gaziano, J.M.; Zaharris, E.; MacFadyen, J.; Danielson, E.; Buring, J.E.; Manson, J.E. A Randomized Factorial Trial of Vitamins C and E and β Carotene in the Secondary Prevention of Cardiovascular Events in Women: Results from the Women’s Antioxidant Cardiovascular Study. *Arch. Intern. Med.* 2007, 167, 1610–1618. [CrossRef] [PubMed]

36. Yan, J.; Fujii, K.; Yao, J.; Kishida, H.; Hosoe, K.; Sawashita, J.; Takeda, T.; Mori, M.; Higuchi, K. Reduced Coenzyme Q10 Supplementation Decelerates Senescence in Samp1 Mice. *Exp. Gerontol* 2006, 41, 130–140. [CrossRef] [PubMed]

37. Lee, C.K.; Pugh, T.D.; Klopp, R.G.; Edwards, J.; Allison, D.B.; Weindruch, R.; Prolla, T.A. The Impact of α-Lipoic Acid, Coenzyme Q10 and Caloric Restriction on Life Span and Gene Expression Patterns in Mice. *Free Radic. Biol. Med.* 2004, 36, 1043–1057. [CrossRef] [PubMed]

38. Miller, E.R., 3rd.; Pastor-Barriuso, R.; Dalal, D.; Riemersma, R.A.; Appel, L.J.; Guallar, E. Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality. *Ann. Intern. Med.* 2005, 142, 37–46. [CrossRef] [PubMed]

39. Vivekananthan, D.P.; Penn, M.S.; Sapp, S.K.; Hsu, A.; Topol, E.J. Use of Antioxidant Vitamins for the Prevention of Cardiovascular Disease: Meta-Analysis of Randomised Trials. *Lancet* 2003, 361, 2017–2023. [CrossRef]

40. Hsieh, C.C.; Lin, B.F. Opposite Effects of Low and High Dose Supplementation of Vitamin E on Survival of Mrl/Lpr Mice. *Nutrition* 2005, 21, 940–948. [CrossRef] [PubMed]

41. Selman, C.; McLaren, J.S.; Meyer, C.; Duncan, J.S.; Redman, P.; Collins, A.R.; Duthie, G.G.; Speakman, J.R. Life-Long Vitamin C Supplementation in Combination with Cold Exposure Does Not Affect Oxidative Damage or Lifespan in Mice, but Decreases Expression of Antioxidant Protection Genes. *Mech. Ageing Dev.* 2006, 127, 897–904. [CrossRef] [PubMed]

42. Morley, A.A.; Trairorn, K. Lack of an Effect of Vitamin E on Lifespan of Mice. *Biogerontology* 2001, 2, 109–112. [CrossRef] [PubMed]

43. Huang, W.Q.; Yi, K.H.; Li, Z.; Wang, H.; Li, M.L.; Cai, L.L.; Lin, H.N.; Lin, Q.; Tzeng, C.M. DNA Methylation Profiling Reveals the Change of Inflammation-Associated Zc3h12d in Leukoaraiosis. *Front. Aging Neurosci.* 2018, 10, 143. [CrossRef] [PubMed]

44. Irvin, M.R.; Aslibekyan, S.; Do, A.; Zhi, D.; Hidalgo, B.; Claas, S.A.; Srinivasasainagendra, V.; Horvath, S.; Tiwari, H.K.; Absher, D.M.; et al. Metabolic and Inflammatory Biomarkers Are Associated with Epigenetic Aging Acceleration Estimates in the Goldn Study. *Clin. Epigenet.* 2018, 10, 56. [CrossRef] [PubMed]

45. Kano, Y.; Soda, K.; Konishi, F. Suppression of LFA-1 Expression by Spermine Is Associated with Enhanced Methylation of ITGAL, the LFA-1 Promoter Area. *PLoS ONE* 2013, 8, e56056. [CrossRef] [PubMed]
46. Soda, K.; Dobashi, Y.; Kano, Y.; Tsujinaka, S.; Konishi, F. Polyamine-Rich Food Decreases Age-Associated Pathology and Mortality in Aged Mice. *Exp. Gerontol.* 2009, 44, 727–732. [CrossRef] [PubMed]

47. Soda, K.; Kano, Y.; Chiba, F.; Koizumi, K.; Miyaki, Y. Increased Polyamine Intake Inhibits Age-Associated Alteration in Global DNA Methylation and 1,2-Dimethylhydrazine-Induced Tumorigenesis. *PLoS ONE* 2013, 8, e64357. [CrossRef] [PubMed]

48. Powers, D.C.; Morley, J.E.; Flood, J.F. Age-Related Changes in LFA-1 Expression, Cell Adhesion, and Pha-Induced Proliferation by Lymphocytes from Senescence-Accelerated Mouse (Sam)-P/8 and Sam-R/1 Substrains. *Cell Immunol.* 1992, 141, 444–456. [CrossRef]

49. Pallis, M.; Robins, A.; Powell, R. Quantitative Analysis of Lymphocyte Cd11a Using Standardized Flow Cytometry. *Scand. J. Immunol.* 1993, 38, 559–564. [CrossRef] [PubMed]

50. Okumura, M.; Fujii, Y.; Takeuchi, Y.; Inada, K.; Nakahara, K.; Matsuda, H. Age-Related Accumulation of LFA-1high Cells in a CD8+ CD45RAhigh T Cell Population. *Eur. J. Immunol.* 1993, 23, 1057–1063. [CrossRef] [PubMed]

51. Chiricolo, M.; Morini, M.C.; Mancini, R.; Beltrandi, E.; Belletti, D.; Conte, R. Cell Adhesion Molecules Cd11a and Cd18 in Blood Monocytes in Old Age and the Consequences for Immunological Dysfunction. Preliminary Results. *Gerontology* 1995, 41, 227–234. [CrossRef] [PubMed]

52. Alonso-Arias, R.; Moro-Garcia, M.A.; Lopez-Vazquez, A.; Rodrigo, L.; Baltar, J.; Garcia, F.M.; Jaurrieta, J.J.; Lopez-Larrea, C. Nkg2d Expression in CD4+ T Lymphocytes as a Marker of Senescence in the Aged Immune System. *Age* 2013, 33, 591–605. [CrossRef] [PubMed]

53. Sandmand, M.; Bruunsgaard, H.; Kemp, K.; Andersen-Ranberg, K.; Pedersen, A.N.; Skinhoj, P.; Pedersen, B.K. Is Ageing Associated with a Shift in the Balance between Type 1 and Type 2 Cytokines in Humans? *Clin. Exp. Immunol.* 2002, 127, 107–114. [CrossRef] [PubMed]

54. Yu, M.; Li, G.; Lee, W.W.; Yuan, M.; Cui, D.; Weyand, C.M.; Goronzy, J.J. Signal Inhibition by the Dual-Specific Phosphatase 4 Impairs T Cell-Dependent B-Cell Responses with Age. *Proc. Natl Acad. Sci. USA* 2012, 109, E879–E888. [CrossRef] [PubMed]

55. Franceschi, C.; Bonafe, M.; Valensin, S.; Olivieri, F.; De Luca, M.; Ottaviani, E.; De Benedictis, G. Inflamm-Aging. An Evolutionary Perspective on Immunosenescence. *Ann. N. Y. Acad. Sci.* 2000, 908, 244–254. [CrossRef] [PubMed]

56. Flesher, D.L.; Sun, X.; Behrens, T.W.; Graham, R.R.; Criswell, L.A. Recent Advances in the Genetics of Systemic Lupus Erythematosus. *Expert Rev. Clin. Immunol.* 2010, 6, 461–479. [CrossRef] [PubMed]

57. Agrawal, A.; Sridharan, A.; Prakash, S.; Agrawal, H. Dendritic Cells and Aging: Consequences for Autoimmunity. *Expert Rev. Clin. Immunol.* 2012, 8, 73–80. [CrossRef] [PubMed]

58. Prasad, S.; Sung, B.; Aggarwal, B.B. Age-Associated Chronic Diseases Require Age-Old Medicine: Role of Chronic Inflammation. *Pert. Med.* 2012, 54, S29–S37. [CrossRef] [PubMed]

59. O’Connor, J.C.; McCusker, R.H.; Strle, K.; Johnson, R.W.; Dantzer, R.; Kelley, K.W. Regulation of IGF-I Function by Proinflammatory Cytokines: At the Interface of Immunology and Endocrinology. *Cell Immunol.* 2008, 252, 91–110. [CrossRef] [PubMed]

60. De Luca, C.; Olefsky, J.M. Inflammation and Insulin Resistance. *FEBS Lett.* 2008, 582, 97–105. [CrossRef] [PubMed]

61. La Ferla, K.; Reimann, C.; Jelkmann, W.; Hellwig-Burgel, T. Inhibition of Erythropoietin Gene Expression Involves the Transcription Factors Gata-2 and NF-κB. *FASEB J.* 2002, 16, 1811–1813. [CrossRef] [PubMed]

62. Sprague, A.H.; Khalil, R.A. Inflammatory Cytokines in Vascular Dysfunction and Vascular Disease. *Biochem. Pharmacol.* 2009, 78, 539–552. [CrossRef] [PubMed]

63. Munoz-Canoves, P.; Scheele, C.; Pedersen, B.K.; Serrano, A.L. Interleukin-6 Myokine Signaling in Skeletal Muscle: A Double-Edged Sword? *FEBS J.* 2013, 280, 4131–4148. [CrossRef] [PubMed]

64. Fulop, T.; Larbi, A.; Pawelec, G. Human T Cell Aging and the Impact of Persistent Viral Infections. *Front. Immunol.* 2013, 4, 271. [CrossRef] [PubMed]

65. Pawelec, G. Immunosenescence: Role of Cytomegalovirus. *Exp. Gerontol.* 2014, 54, 1–5. [CrossRef] [PubMed]

66. Flerioli, M.E.; Ceruti, G.; Comolli, R. Changes in Rat Liver Ornithine Decarboxylase Activity During Ageing and Effect of Stimulation by Dexamethasone. *Exp. Gerontol.* 1976, 11, 153–156. [CrossRef]

67. Yoshinaga, K.; Ishizuka, J.; Evers, B.M.; Townsend, C.M., Jr.; Thompson, J.C. Age-Related Changes in Polyamine Biosynthesis after Fasting and Refeeding. *Exp. Gerontol.* 1993, 28, 565–572. [CrossRef]
68. Janne, J.; Raina, A. On the Stimulation of Ornithine Decarboxylase and RNA Polymerase Activity in Rat Liver after Treatment with Growth Hormone. Biochim. Biophys. Acta. 1969, 174, 769–772. [CrossRef]

69. Bedford, M.R.; Smith, T.K.; Summers, J.D. Effect of Dietary Ornithine on Renal and Hepatic Polyamine Synthesis. Ann. Nutr. Metab. 1988, 32, 265–270. [CrossRef] [PubMed]

70. Schleifer, R.; Duranton, B.; Gosse, F.; Hasselmann, M.; Raul, F. Blood Polyamine Levels after Oral Ornithine Load, a Diagnostic Marker of Hyperproliferative Premalignant and Malignant Stages in a Model of Colon Carcinogenesis. Cancer Detect. Prev. 2000, 24, 542–548. [PubMed]

71. Teixeira, D.; Santaolalria, M.L.; Meneu, V.; Alonso, E. Dietary Arginine Slightly and Variably Affects Tissue Polyamine Levels in Male Swiss Albino Mice. J. Nutr. 2002, 132, 3715–3720. [CrossRef] [PubMed]

72. Laitinen, S.I.; Laitinen, P.H.; Hietala, O.A.; Pajunen, A.E.; Piha, R.S. Developmental Changes in Mouse Brain Polyamine Metabolism. Neurochem. Res. 1982, 7, 1477–1485. [CrossRef] [PubMed]

73. Das, R.; Kanungo, M.S. Activity and Modulation of Ornithine Decarboxylase and Concentrations of Polyamines in Various Tissues of Rats as a Function of Age. Exp. Gerontol. 1982, 17, 95–103. [CrossRef]

74. Zhang, M.; Caragine, T.; Wang, H.; Cohen, P.S.; Botchkina, G.; Soda, K.; Bianchi, M.; Ulrich, P.; Cerami, A.; Sherry, B.; et al. Spermine Inhibits Proinflammatory Cytokine Synthesis in Human Mononuclear Cells: A Counterregulatory Mechanism That Restrains the Immune Response. J. Exp. Med. 1997, 185, 1759–1768. [CrossRef] [PubMed]

75. Gillis, S.; Kozak, R.; Durante, M.; Weksler, M.E. Immunological Studies of Aging. Decreased Production and Response to T Cell Growth Factor by Lymphocytes from Aged Humans. J. Clin. Invest. 1981, 67, 937–942. [CrossRef] [PubMed]

76. Soda, K. Anti-Aging by Polyamine. Food Style 21 2006, 10, 43–54. Available online: http://www.natto.or.jp/thesis/01polyamine/07.html (accessed on 9 Oct 2018). (In Japanese)

77. Eisenberg, T.; Knauer, H.; Schauer, A.; Büttner, S.; Ruckenstuhl, C.; Carmona-Gutierrez, D.; Ring, J.; Schroeder, S.; Magnes, C.; Antonacci, L.; et al. Induction of Autophagy by Spermidine Promotes Longevity. Nat. Cell Biol. 2009, 11, 1305–1314. [CrossRef] [PubMed]

78. Soda, K. The Mechanisms by Which Polyamines Accelerate Tumor Spread. J. Exp. Clin. Cancer Res. 2011, 30, 95. [CrossRef] [PubMed]

79. Weiss, T.S.; Bernhardt, G.; Buschauer, A.; Thasler, W.E.; Dolgner, D.; Zirngibl, H.; Jauch, K.W. Polyamine levels of human colorectal adenocarcinomas are correlated with tumor stage and grade. Int. J. Colorectal Dis. 2002, 17, 381–387. [CrossRef] [PubMed]

80. Upp, J.R., Jr; Saydjari, R.; Townsend, C.M., Jr; Singh, P.; Barranco, S.C.; Thompson, J.C. Polyamine Levels and Gastrin Receptors in Colon Cancers. Ann. Surg. 1988, 207, 662–669. [CrossRef] [PubMed]

81. Gallesio, C.; Colombatto, S.; Modica, R. Free and Acetylated Polyamines as Markers of Oral Cavity Tumors. Oral Surg. Oral Med. Oral Pathol. 1994, 77, 167–171. [CrossRef]

82. Becciolini, A.; Porciani, S.; Panini, A.; Balzi, M.; Cionini, L.; Bandettini, L. Polyamine Levels in Healthy and Tumor Tissues of Patients with Colon Adenocarcinoma. Dis. Colon Rectum 1991, 34, 167–173. [CrossRef] [PubMed]

83. Loser, C.; Folsch, U.R.; Paprotny, C.; Creutzfeldt, W. Polyamines in Colorectal Cancer. Evaluation of Polyamine Concentrations in the Colon Tissue, Serum, and Urine of 50 Patients with Colorectal Cancer. Cancer 1990, 65, 958–966. [CrossRef]

84. Elworthy, P.; Hitchcock, E. Polyamine Levels in Red Blood Cells from Patient Groups of Different Sex and Age. Biochim. Biophys. Acta. 1989, 993, 212–216. [CrossRef]

85. Cipolla, B.G.; Havouis, R.; Moulinoux, J.P. Polyamine Contents in Current Foods: A Basis for Polyamine from Food and Drink. J. Biochem. 2006, 139, 81–90. [CrossRef] [PubMed]

86. Nishimura, K.; Shiina, R.; Kashiwagi, K.; Igarashi, K. Decrease in Polyamines with Aging and Their Ingestion from Food and Drink. J. Biochem. 2006, 139, 81–90. [CrossRef] [PubMed]

87. Nishibori, N.; Fujihara, S.; Akatuki, T. Amounts of Polyamines in Foods in Japan and Intake by Japanese. Food Chem. 2006, 100. [CrossRef]

88. Soda, K.; Mogi, S.; Shiina, M.; Kawabata, N. The Polyamine Content in Various Foods on a Calorie Basis. JACOBS J. Food Nutr. 2017, 4, 029.

89. Uda, K.; Tsujikawa, T.; Fujiyama, Y.; Bamba, T. Rapid Absorption of Luminal Polyamines in a Rat Small Intestine Ex Vivo Model. J. Gastroenterol. Hepatol. 2003, 18, 554–559. [CrossRef] [PubMed]
105. Pucciarelli, S.; Moreschini, B.; Micozzi, D.; De Fronzo, G.S.; Carpi, F.M.; Polzonetti, V.; Garcea, R.; Daino, L.; Pascale, R.; Simile, M.M.; Puddu, M.; Ruggiu, M.E.; Seddaiu, M.A.; Satta, G.; Soda, K.; Uemura, T.; Igarashi, K.; Fukui, T. Increased Polyamine Intake by Being Adherent to Traditional Japanese Diet Increases Blood Spermine Levels and Inhibits Pro-Inflammatory Status—An Interventional Study. Unpublished.

106. Watanabe, S.; Sato, S.; Nagase, S.; Shimosato, K.; Ohkuma, S. Effects of Methotrexate and Cyclophosphamide on Polyamine Levels in Various Tissues of Rats. J. Drug Target 1999, 7, 197–205. [CrossRef] [PubMed]

107. Binh, P.N.T.; Soda, K.; Kawakami, M. Mediterranean Diet and Polyamine Intake: Possible Consequence of Increased Polyamine Intake to Inhibition of Age-Associated Disease. Nutr. Diet. Suppl. 2011, 3, 1–7.

108. Fukui, T.; Soda, K.; Takao, K.; Rikiyama, T. Extracellular spermine activates DNA methyltransferase 3A and 3B. Unpublished.

109. Bestor, T.; Laudano, A.; Mattaliano, R.; Ingram, V. Cloning and Sequencing of a Cdnna Encoding DNA Methyltransferase of Mouse Cells. The Carboxyl-Terminal Domain of the Mammalian Enzymes Is Related to Bacterial Restriction Methyltransferases. J. Mol. Biol. 1988, 203, 971–983. [CrossRef]

110. Garcea, R.; Daino, L.; Pascale, R.; Simile, M.M.; Puddu, M.; Ruggiu, M.E.; Seddaiu, M.A.; Satta, G.; Sequenza, M.J.; Feo, F. Protooncogene Methylation and Expression in Regenerating Liver and Preneoplastic Liver Nodules Induced in the Rat by Diethylnitrosamine: Effect of Variations of S-Adenosylmethionine: S-Adenosylhomocysteine Ratio. Carcinogenesis 1989, 10, 1183–1192. [CrossRef] [PubMed]
111. Lovaas, E.; Carlin, G. Spermine: An Anti-Oxidant and Anti-Inflammatory Agent. Free Radic. Biol. Med. 1991, 11, 455–461. [CrossRef]

112. Lagishetty, C.V.; Naik, S.R. Polyamines: Potential Anti-Inflammatory Agents and Their Possible Mechanism of Action. Indian J. Pharmacol. 2008, 40, 121–125. [PubMed]

113. Choi, Y.H.; Park, H.Y. Anti-Inflammatory Effects of Spermidine in Lipopolysaccharide-Stimulated Bv2 Microglial Cells. J. Biomed. Sci. 2012, 19, 31. [CrossRef] [PubMed]

114. Paul, S.; Kang, S.C. Natural Polyamine Inhibits Mouse Skin Inflammation and Macrophage Activation. Inflamm. Res. 2012, 62, 681–688. [CrossRef] [PubMed]

115. Zhou, S.; Gu, J.; Liu, R.; Wei, S.; Wang, Q.; Shen, H.; Dai, Y.; Zhou, H.; Zhang, F.; Lu, L. Spermine Alleviates Acute Liver Injury by Inhibiting Liver-Resident Macrophage Pro-Inflammatory Response through Atg5-Dependent Autophagy. Front. Immunol. 2018, 9, 948. [CrossRef] [PubMed]

116. Tadolini, B.; Cabrini, L.; Landi, L.; Varani, E.; Pasquali, P. Polyamine Binding to Phospholipid Vesicles and Inhibition of Lipid Peroxidation. Biochem. Biophys. Res. Commun. 1984, 122, 550–555. [CrossRef]

117. Khan, A.U.; Di Mascio, P.; Medeiros, M.H.; Wilson, T. Spermine and Spermidine Protection of Plasmid DNA against Single-Strand Breaks Induced by Singlet Oxygen. Proc. Natl. Acad. Sci. USA 1992, 89, 11428–11430. [CrossRef] [PubMed]

118. Goss, S.P.; Hogg, N.; Kalyanaraman, B. The Antioxidant Effect of Spermine Nonoate in Human Low-Density Lipoprotein. Chem. Res. Toxicol. 1995, 8, 800–806. [CrossRef] [PubMed]

119. Marzabadi, M.R.; Lovaas, E. Spermine Prevent Iron Accumulation and Depress Lipofuscin Accumulation in Cultured Myocardial Cells. Free Radic. Biol. Med. 1996, 21, 375–381. [CrossRef]

120. Farbiszewski, R.; Bielawska, A.; Szymanska, M.; Skrzydlewska, E. Spermine partially normalizes in vivo antioxidant defense potential in certain brain regions in transiently hypoperfused rat brain. Neurochem. Res. 1996, 21, 1497–1503. [CrossRef] [PubMed]

121. Ha, H.C.; Sirisoma, N.S.; Kuppusamy, P.; Zweier, J.L.; Woster, P.M.; Casero, R.A., Jr. The Natural Polyamine Spermine Functions Directly as a Free Radical Scavenger. Proc. Natl. Acad. Sci. USA 1998, 95, 11140–11145. [CrossRef] [PubMed]

122. Jung, I.L.; Oh, T.J.; Kim, I.G. Abnormal Growth of Polyamine-Deficient Escherichia Coli Mutant Is Partially Caused by Oxidative Stress-Induced Damage. Arch. Biochem. Biophys. 2003, 418, 125–132. [CrossRef] [PubMed]

123. Chattopadhyay, M.K.; Tabor, C.W.; Tabor, H. Polyamines Protect Escherichia Coli Cells from the Toxic Effect of Oxygen. Proc. Natl. Acad. Sci. USA 2003, 100, 2261–2265. [CrossRef] [PubMed]

124. Belle, N.A.; Dalmolin, G.D.; Fonini, G.; Rubin, M.A.; Rocha, J.B. Polyamines Reduces Lipid Peroxidation Induced by Different Pro-Oxidant Agents. Brain Res. 2004, 1008, 245–251. [CrossRef] [PubMed]

125. Gaboriau, F.; Vaulthier, M.; Moulinoux, J.P.; Delcros, J.G. Antioxidative Properties of Natural Polyamines and Dimethylsilane Analogues. Redox. Rep. 2005, 10, 9–18. [CrossRef] [PubMed]

126. Fujiwasa, S.; Kadoma, Y. Kinetic Evaluation of Polyamines as Radical Scavengers. Anticancer Res. 2005, 25, 965–969. [PubMed]

127. Sava, I.G.; Battaglia, V.; Rossi, C.A.; Salvi, M.; Toninello, A. Free Radical Scavenging Action of the Natural Polyamine Spermine in Rat Liver Mitochondria. Free Radic. Biol. Med. 2006, 41, 1272–1281. [CrossRef] [PubMed]

128. Rider, J.E.; Hacker, A.; Mackintosh, C.A.; Pegg, A.E.; Woster, P.M.; Casero, R.A., Jr. Spermine and Spermidine Mediate Protection against Oxidative Damage Caused by Hydrogen Peroxide. Amino Acids 2007, 33, 231–240. [CrossRef] [PubMed]

129. Nayvelt, I.; Hyvonen, M.T.; Alhonen, L.; Pandya, I.; Thomas, T.; Khomutov, A.R.; Vepsalainen, J.; Patel, R.; Keinanen, T.A.; Thomas, T.J. DNA Condensation by Chiral Alpha-Methylated Polyamine Analogues and Protection of Cellular DNA from Oxidative Damage. Biomacromolecules 2010, 11, 97–105. [CrossRef] [PubMed]

130. Jeong, J.W.; Cha, H.J.; Han, M.H.; Hwang, S.J.; Lee, D.S.; Yoo, J.S.; Choi, I.W.; Kim, S.; Kim, H.S.; Kim, G.Y.; et al. Spermidine Protects against Oxidative Stress in Inflammation Models Using Macrophages and Zebrafish. Biomol. Ther. 2018, 26, 146–156. [CrossRef] [PubMed]

131. Courdi, A.; Milano, G.; Bouclier, M.; Lalanne, C.M. Radiosensitization of Human Tumor Cells by Alpha-Difluoromethylornithine. Int. J. Cancer 1986, 38, 103–107. [CrossRef] [PubMed]
132. Arundel, C.M.; Nishioka, K.; Tofilon, P.J. Effects of Alpha-Difluoromethylornithine-Induced Polyamine Depletion on the Radiosensitivity of a Human Colon Carcinoma Cell Line. Radiat. Res. 1988, 114, 634–640. [CrossRef] [PubMed]
133. Held, K.D.; Awad, S. Effects of Polyamines and Thiols on the Radiation Sensitivity of Bacterial Transforming DNA. Int. J. Radiat. Biol. 1991, 59, 699–710. [CrossRef] [PubMed]
134. Snyder, R.D.; Schroeder, K.K. Radiosensitivity of Polyamine-Depleted Hela Cells and Modulation by the Aminothiol Wr-1065. Radiat. Res. 1994, 137, 67–75. [CrossRef] [PubMed]
135. Williams, J.R.; Casero, R.A.; Dillehay, L.E. The Effect of Polyamine Depletion on the Cytotoxic Response to Puva, Gamma Rays and Uvc in V79 Cells in Vitro. Biochem. Biophys. Res. Commun. 1994, 201, 1–7. [CrossRef] [PubMed]
136. Snyder, R.D.; Schroeder, K.K. Radiosensitivity of Polyamine-Depleted Hela Cells and Modulation by the Aminothiol Wr-1065. Radiat. Res. 1994, 137, 67–75. [CrossRef] [PubMed]
137. Williams, J.R.; Casero, R.A.; Dillehay, L.E. The Effect of Polyamine Depletion on the Cytotoxic Response to Puva, Gamma Rays and Uvc in V79 Cells in Vitro. Biochem. Biophys. Res. Commun. 1994, 201, 1–7. [CrossRef] [PubMed]
138. Snyder, R.D.; Schroeder, K.K. Radiosensitivity of Polyamine-Depleted Hela Cells and Modulation by the Aminothiol Wr-1065. Radiat. Res. 1994, 137, 67–75. [CrossRef] [PubMed]
139. Snyder, R.D.; Schroeder, K.K. Radiosensitivity of Polyamine-Depleted Hela Cells and Modulation by the Aminothiol Wr-1065. Radiat. Res. 1994, 137, 67–75. [CrossRef] [PubMed]
140. Snyder, R.D.; Schroeder, K.K. Radiosensitivity of Polyamine-Depleted Hela Cells and Modulation by the Aminothiol Wr-1065. Radiat. Res. 1994, 137, 67–75. [CrossRef] [PubMed]
141. Snyder, R.D.; Schroeder, K.K. Radiosensitivity of Polyamine-Depleted Hela Cells and Modulation by the Aminothiol Wr-1065. Radiat. Res. 1994, 137, 67–75. [CrossRef] [PubMed]
142. Snyder, R.D.; Schroeder, K.K. Radiosensitivity of Polyamine-Depleted Hela Cells and Modulation by the Aminothiol Wr-1065. Radiat. Res. 1994, 137, 67–75. [CrossRef] [PubMed]
143. Snyder, R.D.; Schroeder, K.K. Radiosensitivity of Polyamine-Depleted Hela Cells and Modulation by the Aminothiol Wr-1065. Radiat. Res. 1994, 137, 67–75. [CrossRef] [PubMed]
144. Snyder, R.D.; Schroeder, K.K. Radiosensitivity of Polyamine-Depleted Hela Cells and Modulation by the Aminothiol Wr-1065. Radiat. Res. 1994, 137, 67–75. [CrossRef] [PubMed]
145. Snyder, R.D.; Schroeder, K.K. Radiosensitivity of Polyamine-Depleted Hela Cells and Modulation by the Aminothiol Wr-1065. Radiat. Res. 1994, 137, 67–75. [CrossRef] [PubMed]
151. Okumura, S.; Teratani, T.; Fujimoto, Y.; Zhao, X.; Tsuruyama, T.; Masano, Y.; Kasahara, N.; Iida, T.; Yagi, S.; Uemura, T.; et al. Oral Administration of Polyamines Ameliorates Liver Ischemia/Reperfusion Injury and Promotes Liver Regeneration in Rats. Liver Transpl. 2016, 22, 1231–1244. [CrossRef] [PubMed]
152. Kucharski, R.; Maleszka, J.; Foret, S.; Maleszka, R. Nutritional Control of Reproductive Status in Honeybees Via DNA Methylation. Science 2008, 319, 1827–1830. [CrossRef] [PubMed]
153. Wang, L.; Shangguan, S.; Xin, Y.; Chang, S.; Wang, Z.; Lu, X.; Wu, L.; Niu, B.; Zhang, T. Folate Deficiency Disturbs Hsa-Let-7 G Level through Methylation Regulation in Neural Tube Defects. J. Cell Mol. Med. 2017, 21, 3244–3253. [CrossRef] [PubMed]
154. Toriyama, M.; Toriyama, M.; Wallingford, J.B.; Finnell, R.H. Folate-Dependent Methylation of Septins Governs Ciliogenesis During Neural Tube Closure. FASEB J. 2017, 31, 3622–3635. [CrossRef] [PubMed]
155. Degroote, S.; Hunting, D.; Takser, L. Periconceptional Folate Deficiency Leads to Autism-Like Traits in Wistar Rat Offspring. Neurotoxicol. Teratol. 2018, 66, 132–138. [CrossRef] [PubMed]
156. Fekete, K.; Berti, C.; Cetin, I.; Hermoso, M.; Koletzko, B.V.; Decsi, T. Perinatal Folate Supply: Relevance in Health Outcome Parameters. Matern. Child. Nutr. 2010, 6 (Suppl. 2), 23–38. [CrossRef]
157. Li, W.; Li, Z.; Li, S.; Wang, X.; Wilson, J.X.; Huang, G. Periconceptional Folic Acid Supplementation Benefit to Development of Early Sensory-Motor Function through Increase DNA Methylation in Rat Offspring. Nutrients 2018, 10, 292. [CrossRef] [PubMed]
158. Jin, C.; Zhuo, Y.; Wang, J.; Zhao, Y.; Xuan, Y.; Mou, D.; Liu, H.; Zhou, P.; Fang, Z.; Che, L.; et al. Methyl Donors Dietary Supplementation to Gestating Sows Diet Improves the Growth Rate of Offspring and Is Associating with Changes in Expression and DNA Methylation of Insulin-Like Growth Factor-1 Gene. J. Anim. Physiol. Anim. Nutr. 2018, 102, 1340–1350. [CrossRef] [PubMed]
159. Steegers-Theunissen, R.P.; Obermann-Borst, S.A.; Kremer, D.; Lindemans, J.; Siebel, C.; Steegers, E.A.; Slagboom, P.E.; Heijmans, B.T. Periconceptional Maternal Folic Acid Use of 400 Microg Per Day Is Related to Increased Methylation of the IGF2 Gene in the Very Young Child. PLoS ONE 2009, 4, e7845. [CrossRef] [PubMed]
160. Cooper, W.N.; Khulan, B.; Owens, S.; Elks, C.E.; Seidel, V.; Belteki, G.; Affara, N.A.; Constância, M.; et al. DNA Methylation Profiling at Imprinted Loci after Periconceptional Micronutrient Supplementation in Humans: Results of a Pilot Randomized Controlled Trial. FASEB J. 2012, 26, 1782–1790. [CrossRef] [PubMed]
161. Joubert, B.R.; den Dekker, H.T.; Felix, J.F.; Bohlin, J.; Ligthart, S.; Beckett, E.; Tiemeier, H.; van Meurs, J.B.; Uitterlinden, A.G.; Hofman, A.; et al. Maternal Plasma Folate Impacts Differential DNA Methylation in an Epigenome-Wide Meta-Analysis of Newborns. Nat. Commun. 2016, 7, 10577. [CrossRef] [PubMed]
162. Pauwels, S.; Ghosh, M.; Duca, R.C.; Bekaeart, B.; Freson, K.; Huybrechts, I.; Langie, S.A.S.; Koppen, G.; Devlieger, R.; Godderis, L. Dietary and Supplemental Maternal Methyl-Group Donor Intake and Cord Blood DNA Methylation. Epigenetics 2017, 12, 1–10. [CrossRef] [PubMed]
163. Pauwels, S.; Ghosh, M.; Duca, R.C.; Bekaeart, B.; Freson, K.; Huybrechts, I.; Langie, S.A.S.; Koppen, G.; Devlieger, R.; Godderis, L. Maternal Intake of Methyl-Group Donors Affects DNA Methylation of Metabolic Genes in Infants. Clin. Epigenet. 2017, 9, 16. [CrossRef] [PubMed]
164. Kochmanski, J.; Marchlewicz, E.H.; Cavalcante, R.G.; Sartor, M.A.; Dolinoy, D.C. Age-Related Epigenome-Wide DNA Methylation and Hydroxymethylation in Longitudinal Mouse Blood. Epigenetics 2018, 13, 779–792. [CrossRef] [PubMed]
165. Zhang, Z.; Deng, C.; Lu, Q.; Richardson, B. Age-Dependent DNA Methylation Changes in the ITGAL (Cd11a) Promoter. Mech. Ageing Dev. 2002, 123, 1257–1268. [CrossRef]
166. Nguyen, A.; Leblond, F.; Mamarbachi, M.; Geoffroy, S.; Thorin, E. Age-Dependent Demethylation of Sod2 Promoter in the Mouse Femoral Artery. Oxid. Med. Cell Longev. 2016, 2016, 8627384. [CrossRef] [PubMed]
167. Avrahami, D.; Li, C.; Zhang, J.; Schug, J.; Avrahami, R.; Rao, S.; Studler, M.B.; Burger, L.; Schübeler, D.; Glaser, B.; et al. Aging-Dependent Demethylation of Regulatory Elements Correlates with Chromatin State and Improved β Cell Function. Cell Metab. 2015, 22, 619–632. [CrossRef] [PubMed]
168. Takasugi, M.; Hayakawa, K.; Arai, D.; Shiota, K. Age- and Sex-Dependent DNA Hypomethylation Controlled by Growth Hormone in Mouse Liver. Mech. Ageing Dev. 2013, 134, 331–337. [CrossRef] [PubMed]
169. Thalheim, T.; Herberg, M.; Galle, J. Linking DNA Damage and Age-Related Promoter DNA Hyper-Methylation in the Intestine. Genes 2018, 9, 17. [CrossRef] [PubMed]
170. Khalil, H.; Tazi, M.; Caution, K.; Ahmed, A.; Kanneganti, A.; Assani, K.; Kopp, B.; Marsh, C.; Dakhllallah, D.; Amer, A.O. Aging Is Associated with Hypermethylation of Autophagy Genes in Macrophages. Epigenetics 2016, 11, 381–388. [CrossRef] [PubMed]

171. Gale, C.R.; Marioni, R.E.; Harris, S.E.; Starr, J.M.; Deary, I.J. DNA Methylation and the Epigenetic Clock in Relation to Physical Frailty in Older People: The Lothian Birth Cohort 1936. Clin. Epigenet. 2018, 10, 101. [CrossRef] [PubMed]

172. Ciccarone, F.; Malavolta, M.; Calabrese, R.; Guastafierro, T.; Bacalini, M.G.; Reale, A.; Franceschi, C.; Capri, M.; Hervonen, A.; Hurme, M.; et al. Age-Dependent Expression of DNMT1 and DNMT3B in PBMCs from a Large European Population Enrolled in the Mark-Age Study. Aging Cell 2016, 15, 755–765. [CrossRef] [PubMed]

173. Issa, J.P. Aging and Epigenetic Drift: A Vicious Cycle. J. Clin. Investig. 2014, 124, 24–29. [CrossRef] [PubMed]

174. Oliveira, A.M.; Hemstedt, T.J.; Bading, H. Rescue of Aging-Associated Decline in Dnmt3a2 Expression Restores Cognitive Abilities. Nat. Neurosci. 2012, 15, 1111–1113. [CrossRef] [PubMed]

175. Maegawa, S.; Hinkal, G.; Kim, H.S.; Shen, L.; Zhang, J.; Zhang, N.; Liang, S.; Donehower, L.A.; Issa, J.P. Widespread and Tissue Specific Age-Related DNA Methylation Changes in Mice. Genome Res. 2010, 20, 332–340. [CrossRef] [PubMed]

176. Bolund, A.C.S.; Starnawska, A.; Miller, M.R.; Schlunssen, V.; Backer, V.; Borglum, A.D.; Christensen, K.; Tan, Q.; Christiansen, L.; Sigsgaard, T. Lung Function Discordance in Monozygotic Twins and Associated Differences in Blood DNA Methylation. Clin. Epigenet. 2017, 9, 132. [CrossRef] [PubMed]

177. Bell, J.T.; Tsai, P.C.; Yang, T.P.; Pidsley, R.; Nisbet, J.; Glass, D.; Mangino, M.; Zhang, F.; Valdes, A.; et al. Epigenome-Wide Scans Identify Differentially Methylated Regions for Age and Age-Related Phenotypes in a Healthy Aging Population. PLoS Genet. 2012, 8, e1002629. [CrossRef] [PubMed]

178. De F C Lichtenfels, A.J.; van der Plaat, D.A.; de Jong, K.; van Diemen, C.C.; Postma, D.S.; Nedeljkovic, I.; Bell, J.T.; Tsai, P.C.; Yang, T.P.; Pidsley, R.; Nisbet, J.; Glass, D.; Mangino, M.; Zhang, F.; Valdes, A.; et al. Epigenome-Wide Scans Identify Differentially Methylated Regions for Age and Age-Related Phenotypes in a Healthy Aging Population. PLoS Genet. 2012, 8, e1002629. [CrossRef] [PubMed]

179. Nwanaji-Enwerem, J.C.; Colicino, E.; Dai, L.; Cayir, A.; Sanchez-Guerra, M.; Laue, H.E.; Nguyen, V.T.; Di, Q.; Just, A.C.; Hou, L.; et al. Impacts of the Mitochondrial Genome on the Relationship of Long-Term Ambient Fine Particle Exposure with Blood DNA Methylation Age. Environ. Sci. Technol. 2017, 51, 8185–8195. [CrossRef] [PubMed]

180. Chen, R.; Meng, X.; Zhao, A.; Wang, C.; Yang, C.; Li, H.; Cai, J.; Zhao, Z.; Kan, H. DNA Hypermethylation and Its Mediation in the Effects of Fine Particulate Air Pollution on Cardiovascular Biomarkers: A Randomized Crossover Trial. Environ. Int. 2016, 94, 614–619. [CrossRef] [PubMed]

181. Wang, C.; Chen, R.; Shi, M.; Cai, J.; Shi, J.; Yang, C.; Li, H.; Lin, Z.; Meng, X.; Liu, C.; et al. Possible Mediation by Methylation in Acute Inflammation Following Personal Exposure to Fine Particulate Air Pollution. Am. J. Epidemiol. 2018, 187, 484–493. [CrossRef] [PubMed]

182. Panni, T.; Mehta, A.J.; Schwartz, J.D.; Baccarelli, A.A.; Just, A.C.; Wolf, K.; Wahl, S.; Cyrys, J.; Kunze, S.; Strauch, K.; et al. Genome-Wide Analysis of DNA Methylation and Fine Particulate Matter Air Pollution in Three Study Populations: Kora F3, Kora F4, and the Normative Aging Study. Environ. Health Perspect. 2016, 124, 983–990. [CrossRef] [PubMed]

183. Ward-Caviness, C.K.; Nwanaji-Enwerem, J.C.; Colicino, E.; Trevisi, L.; Kloog, I.; Just, A.C.; Vokonas, P.; Cyrys, J.; et al. Long-Term Exposure to Air Pollution Is Associated with Biological Aging. Oncotarget 2016, 7, 74510–74525. [CrossRef] [PubMed]

184. Maghbooli, Z.; Hossein-Nezhad, A.; Adabi, E.; Asadollah-Pour, E.; Sadeghi, M.; Mohammad-Nabi, S.; Zakeri, L.; Malek Hosseini, A.A.; Radmehr, M.; Faghihi, F.; et al. Air Pollution During Pregnancy and Placental Adaptation in the Levels of Global DNA Methylation. PLoS ONE 2018, 13, e0199772. [CrossRef] [PubMed]

185. Meyer, K.F.; Verkaik-Schakel, R.N.; Timens, W.; Kobzik, L.; Ploos, T.; Hylkema, M.N. The Fetal Programming Effect of Prenatal Smoking on IGF1R and IGF1 Methylation Is Organ- and Sex-Specific. Epigenetics 2017, 12, 1076–1091. [CrossRef] [PubMed]

186. Drake, A.J.; O'Shaughnessy, P.J.; Bhattacharya, S.; Monteiro, A.; Kerrigan, D.; Goetz, S.; Raab, A.; Rhind, S.M.; Sinclair, K.D.; Meharg, A.A.; et al. In Utero Exposure to Cigarette Chemicals Induces Sex-Specific Disruption of One-Carbon Metabolism and DNA Methylation in the Human Fetal Liver. BMC Med. 2015, 13, 18. [CrossRef] [PubMed]
187. Bauer, M.; Fink, B.; Thurmann, L.; Eszlinger, M.; Herberth, G.; Lehmann, I. Tobacco Smoking Differently Influences Cell Types of the Innate and Adaptive Immune System-Indications from Cpg Site Methylation. *Clin. Epigenet.* 2015, 7, 83. [CrossRef] [PubMed]

188. O'Hagan, H.M.; Wang, W.; Sen, S.; Destefano Shields, C.; Lee, S.S.; Zhang, Y.W.; Clements, E.G.; Cai, Y.; van Neste, L.; Easwaran, H.; et al. Oxidative Damage Targets Complexes Containing DNA Methyltransferases, Sirt1, and Polycomb Members to Promoter Cpg Islands. *Cancer Cell* 2011, 20, 606–619. [CrossRef] [PubMed]

189. Vaz, M.; Hwang, S.Y.; Kagiampakis, I.; Phallen, J.; Patil, A.; O’Hagan, H.M.; Murphy, L.; Zahnow, C.A.; Gabrielson, E.; Velculescu, V.E.; et al. Chronic Cigarette Smoke-Induced Epigenomic Changes Precede Sensitization of Bronchial Epithelial Cells to Single-Step Transformation by Kras Mutations. *Cancer Cell* 2017, 32, 360–376. [CrossRef] [PubMed]

190. Zhang, Y.; Elizizouli, M.; Schottker, B.; Holleczek, B.; Nieters, A.; Brenner, H. Smoking-Associated DNA Methylation Markers Predict Lung Cancer Incidence. *Clin. Epigenet.* 2016, 8, 127. [CrossRef] [PubMed]

191. Steenaard, R.V.; Ligthart, S.; Stolk, L.; Peters, M.J.; van Meurs, J.B.; Uitterlinden, A.G.; Hofman, A.; Franco, O.H.; Dehghan, A. Tobacco Smoking Is Associated with Methylation of Genes Related to Coronary Artery Disease. *Clin. Epigenet.* 2015, 7, 54. [CrossRef] [PubMed]

192. Gao, X.; Zhang, Y.; Saum, K.U.; Schottker, B.; Breitling, L.P.; Brenner, H. Tobacco Smoking and Smoking-Related DNA Methylation Are Associated with the Development of Frailty among Older Adults. *Epigenetics* 2017, 12, 149–156. [CrossRef] [PubMed]

193. Gao, X.; Zhang, Y.; Breitling, L.P.; Brenner, H. Relationship of Tobacco Smoking and Smoking-Related DNA Methylation with Epigenetic Age Acceleration. *Onco-target* 2016, 7, 46878–46889. [CrossRef] [PubMed]

194. Ligthart, S.; Steenaard, R.V.; Peters, M.J.; van Meurs, J.B.; Uitterlinden, A.G.; Hofman, A.; Franco, O.H.; Dehghan, A. Tobacco Smoking Is Associated with DNA Methylation of Diabetes Susceptibility Genes. *Diabetologia* 2016, 59, 998–1006. [CrossRef] [PubMed]

195. Liu, C.; Marioni, R.E.; Hedman, Å.K.; Pfeiffer, L.; Tsai, P.C.; Reynolds, L.M.; Just, A.C.; Duan, Q.; Boer, C.G.; Tanaka, T.; et al. A DNA Methylation Biomarker of Alcohol Consumption. *Mol. Psychiatry* 2018, 23, 422–433. [CrossRef] [PubMed]

196. Sharp, G.C.; Arathimos, R.; Reese, S.E.; Page, C.M.; Felix, J.; Kuijpers, L.K.; Liu, C. Cohorts for Heart and Aging Research in Genomic Epidemiology plus (CHARGE+) Methylation Alcohol Working Group; Burrows, K.; et al. Maternal Alcohol Consumption and Offspring DNA Methylation: Findings from Six General Population-Based Birth Cohorts. *Epigenomics* 2018, 10, 27–42. [CrossRef] [PubMed]

197. Denham, J.; O’Brien, B.J.; Harvey, J.T.; Charchar, F.J. Genome-Wide Sperm DNA Methylation Changes after 3 Months of Exercise Training in Humans. *Epigenomics* 2015, 7, 717–731. [CrossRef] [PubMed]

198. Barres, R.; Yan, J.; Egan, B.; Treebak, J.T.; Rasmussen, M.; Fritz, T.; Patlil, A.; O’Hagan, H.M.; Murphy, L.; Zahnow, C.A.; Gabrielson, E.; Velculescu, V.E.; et al. Chronic Cigarette Smoke-Induced Epigenomic Changes Precede Sensitization of Bronchial Epithelial Cells to Single-Step Transformation by Kras Mutations. *Cancer Cell* 2017, 32, 360–376. [CrossRef] [PubMed]

199. Vaz, M.; Hwang, S.Y.; Kagiampakis, I.; Phallen, J.; Patil, A.; O’Hagan, H.M.; Murphy, L.; Zahnow, C.A.; Gabrielson, E.; Velculescu, V.E.; et al. Chronic Cigarette Smoke-Induced Epigenomic Changes Precede Sensitization of Bronchial Epithelial Cells to Single-Step Transformation by Kras Mutations. *Cancer Cell* 2017, 32, 360–376. [CrossRef] [PubMed]

200. Hahn, O.; Grönke, S.; Stubbs, T.M.; Ficz, G.; Hendrich, O.; Krueger, F.; Andrews, S.; Zhang, Q.; Wakelam, M.J.; Beyer, A.; et al. Dietary Restriction Protects from Age-Associated DNA Methylation and Induces Epigenetic Reprogramming of Lipid Metabolism. *Genome Biol.* 2017, 18, 56. [CrossRef] [PubMed]

201. Cole, J.J.; Robertson, N.A.; Rather, M.I.; Thomson, J.P.; McBryan, T.; Sproul, D.; Wang, T.; Brock, C.; Clark, W.; Ideker, T.; et al. Diverse Interventions That Extend Mouse Lifespan Suppress Shared Age-Associated Epigenetic Changes at Critical Gene Regulatory Regions. *Genome Biol.* 2017, 18, 58. [CrossRef] [PubMed]

202. Kim, C.H.; Lee, E.K.; Choi, Y.J.; An, H.J.; Jeong, H.O.; Park, D.; Kim, B.C.; Yu, B.P.; Bhak, J.; Chung, H.Y. Short-Term Calorie Restriction Ameliorates Genomewide, Age-Related Alterations in DNA Methylation. *Aging Cell* 2016, 15, 1074–1081. [CrossRef] [PubMed]
205. Dhingra, R.; Nwanaji-Enwerem, J.C.; Samet, M.; Ward-Caviness, C.K. DNA Methylation Age-Environmental Influences, Health Impacts, and Its Role in Environmental Epidemiology. *Curr. Environ. Health Rep.* 2018, 5, 317–327. [CrossRef] [PubMed]

206. Austin, M.K.; Chen, E.; Ross, K.M.; McEwen, L.M.; Maclsaac, J.L.; Kober, M.S.; Miller, G.E. Early-Life Socioeconomic Disadvantage, Not Current, Predicts Accelerated Epigenetic Aging of Monocytes. *Psychoneuroendocrinology* 2018, 97, 131–134. [CrossRef] [PubMed]

207. Li, J.; Zhu, X.; Yu, K.; Jiang, H.; Zhang, Y.; Wang, B.; Liu, X.; Deng, S.; Hu, J.; Deng, Q.; et al. Exposure to Polycyclic Aromatic Hydrocarbons and Accelerated DNA Methylation Aging. *Environ. Health Perspect.* 2018, 126, 067005. [CrossRef] [PubMed]

208. Ramos, R.B.; Fabris, V.; Lecke, S.B.; Maturana, M.A.; Spritzer, P.M. Association between Global Leukocyte DNA Methylation and Cardiovascular Risk in Postmenopausal Women. *BMC Med. Genet.* 2016, 17, 71. [CrossRef] [PubMed]

209. Li, H.; Guo, Z.; Guo, Y.; Li, M.; Yan, H.; Cheng, J.; Wang, C.; Hong, G. Common DNA Methylation Alterations of Alzheimer’s Disease and Aging in Peripheral Whole Blood. *Oncotarget* 2016, 7, 19089–19098. [PubMed]

210. Marioni, R.E.; Shah, S.; McRae, A.F.; Chen, B.H.; Colicino, E.; Harris, S.E.; Gibson, J.; Henders, A.K.; Redmond, P.; Cox, S.R.; et al. DNA Methylation Age of Blood Predicts All-Cause Mortality in Later Life. *Genome Biol.* 2015, 16, 25. [CrossRef] [PubMed]

211. Watson, C.T.; Roussos, P.; Garg, P.; Ho, D.J.; Azam, N.; Katsel, P.L.; Haroutunian, V.; Sharp, A.J. Genome-Wide DNA Methylation Profiling in the Superior Temporal Gyrus Reveals Epigenetic Signatures Associated with Alzheimer’s Disease. *Genome Med.* 2016, 8, 5. [CrossRef] [PubMed]

212. Horvath, S. DNA Methylation Age of Human Tissues and Cell Types. * Genome Biol.* 2013, 14, R115. [CrossRef]

213. Lopez-Otin, C.; Blasco, M.A.; Partridge, L.; Serrano, M.; Kroemer, G. The Hallmarks of Aging. *Cell* 2013, 153, 1194–1217. [CrossRef] [PubMed]

214. Cruickshanks, H.A.; McBryan, T.; Nelson, D.M.; Vanderkraats, N.D.; Shah, P.P.; van Tuyn, J.; Singh Rai, T.; Brock, C.; Donahue, G.; Dunican, D.S.; et al. Senescent Cells Harbour Features of the Cancer Epigenome. *Nat. Cell Biol.* 2013, 15, 1495–1506. [CrossRef] [PubMed]

215. Kresovich, J.K.; Joyce, B.T.; Gao, T.; Zheng, Y.; Zhang, Z.; Achenbach, C.J.; Murphy, R.L.; Just, A.C.; Shen, J.; Yang, H.; et al. Promoter Methylation of Pgc1a and Pgc1b Predicts Cancer Incidence in a Veteran Cohort. *Epigenomics* 2018, 10, 733–743. [CrossRef] [PubMed]

216. Perna, L.; Zhang, Y.; Mons, U.; Holleczeck, B.; Saum, K.U.; Brenner, H. Epigenetic Age Acceleration Predicts Cancer, Cardiovascular, and All-Cause Mortality in a German Case Cohort. *Clin. Epigenet.* 2016, 8, 64. [CrossRef] [PubMed]

217. Meliso, F.M.; Micali, D.; Silva, C.T.; Sabedot, T.S.; Coetze, S.G.; Koch, A.; Fahlbusch, F.B.; Nounshmehr, H.; Schneider-Stock, R.; Jasiulionis, M.G. Sirt1 Regulates Msd1 During Malignant Melanoma Progression. *Oncotarget* 2017, 8, 114540–114553. [CrossRef] [PubMed]

218. Joyce, B.T.; Gao, T.; Zheng, Y.; Liu, L.; Zhang, W.; Dai, Q.; Shrubsole, M.J.; Hibler, E.A.; Cristofanilli, M.; Zhang, H.; et al. Prospective Changes in Global DNA Methylation and Cancer Incidence and Mortality. *Br. J. Cancer* 2016, 115, 465–472. [CrossRef] [PubMed]

219. Nishida, N.; Iwanishi, M.; Minami, T.; Chishina, H.; Arizumi, T.; Takita, M.; Kitai, S.; Yada, N.; Ida, H.; Hagiwara, S.; et al. Hepatic DNA Methylation Is Affected by Hepatocellular Carcinoma Risk in Patients with and without Hepatitis Virus. *Dig. Dis.* 2015, 33, 745–750. [CrossRef] [PubMed]

220. Ianov, L.; Riva, A.; Kumar, A.; Foster, T.C. DNA Methylation of Synaptic Genes in the Prefrontal Cortex Is Associated with Aging and Age-Related Cognitive Impairment. *Front. Aging Neurosci.* 2017, 9, 249. [CrossRef] [PubMed]

221. Spiers, H.; Hannon, E.; Wells, S.; Williams, B.; Fernandes, C.; Mill, J. Age-Associated Changes in DNA Methylation across Multiple Tissues in an Inbred Mouse Model. *Mech. Ageing Dev.* 2016, 154, 20–23. [CrossRef] [PubMed]

222. Kanannen, L.; Marttila, S.; Nevalainen, T.; Jylhava, J.; Mononen, N.; Kahonen, M.; Raitakari, O.T.; Lehtimaki, T.; Hurme, M. Aging-Associated DNA Methylation Changes in Middle-Aged Individuals: The Young Finns Study. *BMC Genom.* 2016, 17, 103. [CrossRef] [PubMed]
223. Jin, L.; Jiang, Z.; Xia, Y.; Lou, P.; Chen, L.; Wang, H.; Bai, L.; Xie, Y.; Liu, Y.; Li, W.; et al. Genome-Wide DNA Methylation Changes in Skeletal Muscle between Young and Middle-Aged Pigs. *BMC Genom.* **2014**, *15*, 653. [CrossRef] [PubMed]

224. Svane, A.M.; Soerensen, M.; Lund, J.; Tan, Q.; Jylhävää, J.; Wang, Y.; Pedersen, N.L.; Hägg, S.; Debrabant, B.; Deary, I.J.; et al. DNA Methylation and All-Cause Mortality in Middle-Aged and Elderly Danish Twins. *Genes* **2018**, *9*, 78. [CrossRef] [PubMed]

225. Levine, M.E.; Lu, A.T.; Quach, A.; Chen, B.H.; Assimes, T.L.; Bandinelli, S.; Hou, L.; Baccarelli, A.A.; Stewart, J.D.; Li, Y.; et al. An Epigenetic Biomarker of Aging for Lifespan and Healthspan. *Aging* **2018**, *10*, 573–591. [CrossRef] [PubMed]

226. Christiansen, L.; Lenart, A.; Tan, Q.; Vaupel, J.W.; Ariv, A.; McGue, M.; Christensen, K. DNA Methylation Age Is Associated with Mortality in a Longitudinal Danish Twin Study. *Aging Cell* **2016**, *15*, 149–154. [CrossRef] [PubMed]

227. Lin, Q.; Weidner, C.I.; Costa, I.G.; Marioni, R.E.; Ferreira, M.R.; Deary, I.J.; Wagner, W. DNA Methylation Levels at Individual Age-Associated Cpg Sites Can Be Indicative for Life Expectancy. *Aging* **2016**, *8*, 394–401. [CrossRef] [PubMed]

228. Lu, S.; Niu, Z.; Chen, Y.; Tu, Q.; Zhang, Y.; Chen, W.; Tong, W.; Zhang, Z. Repetitive Element DNA Methylation Is Associated with Menopausal Age. *Aging Dis.* **2018**, *9*, 435–443. [CrossRef] [PubMed]

229. Hannum, G.; Guinney, J.; Zhao, L.; Zhang, L.; Hughes, G.; Sadda, S.; Klotzle, B.; Bibikova, M.; Fan, J.B.; Gao, Y.; et al. Genome-Wide Methylation Profiles Reveal Quantitative Views of Human Aging Rates. *Mol. Cell* **2013**, *49*, 359–367. [CrossRef] [PubMed]

230. Ponnaluri, V.K.C.; Esteve, P.O.; Ruse, C.I.; Pradhan, S. S-Adenosylhomocysteine Hydrolase Participates in DNA Methylation Inheritance. *J. Mol. Biol.* **2018**, *430*, 2051–2065. [CrossRef] [PubMed]

231. Esteve, P.O.; Terragni, J.; Deepti, K.; Chin, H.G.; Dai, N.; Espejo, A.; Correa, I.R., Jr; Bedford, M.T.; Pradhan, S. Methyllysine Reader Plant Homeodomain (Phd) Finger Protein 20-Like 1 (Phf20l1) Antagonizes DNA (Cytosine-5) Methyltransferase 1 (DNMT1) Proteasomal Degradation. *J. Biol. Chem.* **2014**, *289*, 8277–8287. [CrossRef] [PubMed]

232. Cohen, H.M.; Griffiths, A.D.; Tawfik, D.S.; Loakes, D. Determinants of Cofactor Binding to DNA Methyltransferases: Insights from a Systematic Series of Structural Variants of S-Adenosylhomocysteine. *Org. Biomol. Chem.* **2005**, *3*, 152–161. [CrossRef] [PubMed]

233. Zhang, B.; Demomme, M.M.; White, C.R.; Leung, K.Y.; Lee, M.B.; Greene, N.D.; Mann, M.R.; Trasler, J.M.; Baltz, J.M. Both the Folate Cycle and Betaine-Homocysteine Methyltransferase Contribute Methyl Groups for DNA Methylation in Mouse Blastocysts. *FASEB J.* **2015**, *29*, 1069–1079. [CrossRef] [PubMed]

234. Frostesjo, L.; Holm, I.; Grahn, B.; Page, A.W.; Bestor, T.H.; Heby, O. Interference with DNA Methyltransferase Activity and Genome Methylation During F9 Teratocarcinoma Stem Cell Differentiation Induced by Polyamine Depletion. *J. Biol. Chem.* **1997**, *272*, 4359–4366. [CrossRef] [PubMed]

235. Altobelli, G.; Bogdarina, I.G.; Stupka, E.; Clark, A.J.; Langley-Evans, S. Genome-Wide Methylation and Gene Expression Changes in Newborn Rats Following Maternal Protein Restriction and Reversal by Folic Acid. *PLoS ONE* **2013**, *8*, e82899. [CrossRef] [PubMed]

236. Yoon, A.; Tammen, S.A.; Park, S.; Han, S.N.; Choi, S.W. Genome-Wide Hepatic DNA Methylation Changes in High-Fat Diet-Induced Obese Mice. *Nutr. Res. Pract.* **2017**, *11*, 105–113. [CrossRef] [PubMed]

237. Choi, S.W.; Tammen, S.A.; Liu, Z.; Friso, S. A Lifelong Exposure to a Western-Style Diet, but Not Aging, Alters Global DNA Methylation in Mouse Colon. *Nutr. Res. Pract.* **2015**, *9*, 358–363. [CrossRef] [PubMed]

238. Van Straten, E.M.; Bloks, V.W.; Huijkm, N.C.; Baller, J.F.; van Meer, H.; Lutjohann, D.; Kuipers, F.; Plosch, T. The Liver X-Receptor Gene Promoter Is Hypermethylated in a Mouse Model of Prenatal Protein Restriction. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **2010**, *298*, R275–R282. [CrossRef] [PubMed]

239. Kumat, P.K.; Vacek, J.C.; Kalani, A.; Tyagi, N. Homocysteine Induced Cerebrovascular Dysfunction: A Link to Alzheimer’s Disease Etiology. *Open Neurol. J.* **2015**, *9*, 9–14. [CrossRef] [PubMed]
242. Xie, J.C.; Lin, Y.Y.; Liu, X.H.; Zhao, Y.C.; Ma, X.Y.; Yu, J.; Liu, X.Y.; Zhao, Y.X. Homocysteine Is Associated with Exaggerated Morning Blood Pressure Surge in Patients with Acute Ischemic Stroke. J. Stroke Cerebrovasc. Dis. 2018, 27, 2650–2656. [CrossRef] [PubMed]

243. Snyder, H.M.; Corriveau, R.A.; Craft, S.; Faber, J.E.; Greenberg, S.M.; Knopman, D.; Lamb, B.T.; Montine, T.J.; Nedergaard, M.; Schaffer, C.B.; et al. Vascular Contributions to Cognitive Impairment and Dementia Including Alzheimer’s Disease. Alzheimers Dement. 2015, 11, 710–717. [CrossRef] [PubMed]

244. Okura, T.; Miyoshi, K.; Irita, J.; Enomoto, D.; Nagao, T.; Kukida, M.; Tanino, A.; Kudo, K.; Pei, Z.; Higaki, J. Hyperhomocysteinemia Is One of the Risk Factors Associated with Cerebrovascular Stiffness in Hypertensive Patients, Especially Elderly Males. Sci. Rep. 2014, 4, 5663. [CrossRef] [PubMed]

245. Shah, H.; Jan, M.U.; Aaltaf, A.; Salahudin, M. Correlation of Hyper-Homocysteinemia with Coronary Artery Disease in Absence of Conventional Risk Factors among Young Adults. J. Saudi. Heart Assoc. 2018, 30, 305–310. [CrossRef] [PubMed]

246. Catena, C.; Colussi, G.; Nait, F.; Capobianco, F.; Sechi, L.A. Elevated Homocysteine Levels Are Associated with the Metabolic Syndrome and Cardiovascular Events in Hypertensive Patients. Am. J. Hypertens. 2015, 28, 943–950. [CrossRef] [PubMed]

247. Catena, C.; Colussi, G.; Nait, F.; Sechi, L.A. Subclinical Carotid Artery Disease and Plasma Homocysteine Levels in Patients with Hypertension. J. Am. Soc. Hypertens. 2015, 9, 167–175. [CrossRef] [PubMed]

248. Choi, J.W.; Lee, M.H.; Fujii, T.; Fujii, N.; Moon, Y. Association of the Urine Homocysteine/Creatinine Ratio to Proinflammatory Cytokine, Natural Anticoagulant, and Nitric Oxide Levels in Cerebrovascular Disease. Ann. Clin. Lab. Sci. 2014, 44, 461–465. [PubMed]

249. Schaffer, A.; Verdoia, M.; Cassetti, E.; Marino, P.; Suryapranata, H.; De Luca, G.; Novara Atherosclerosis Study, G. Relationship between Homocysteine and Coronary Artery Disease. Results from a Large Prospective Cohort Study. Thromb. Res. 2014, 134, 288–293. [CrossRef] [PubMed]

250. Miwa, K.; Tanaka, M.; Okazaki, S.; Yagita, Y.; Sakaguchi, M.; Mochizuki, H.; Kitagawa, K. Increased Total Homocysteine Levels Predict the Risk of Incident Dementia Independent of Cerebral Small-Vessel Diseases and Vascular Risk Factors. J. Alzheimers Dis. 2016, 49, 503–513. [CrossRef] [PubMed]

251. Jadavji, N.M.; Farr, T.D.; Lips, J.; Khalil, A.A.; Boehm-Sturm, P.; Foddis, M.; Harms, C.; Fuchtemeier, M.; Dirnagl, U. Elevated Levels of Plasma Homocysteine, Deficiencies in Dietary Folic Acid and Uracil-DNA Glycosylase Impair Learning in a Mouse Model of Vascular Cognitive Impairment. Behav. Brain Res. 2015, 283, 215–226. [CrossRef] [PubMed]

252. Kamat, P.K.; Kyles, P.; Kalani, A.; Tyagi, N. Hydrogen Sulfide Ameliorates Homocysteine-Induced Alzheimer’s Disease-Like Pathology, Blood-Brain Barrier Disruption, and Synaptic Disorder. Mol. Neurobiol. 2016, 53, 2451–2467. [CrossRef] [PubMed]

253. Alvarez-Sanchez, N.; Alvarez-Rios, A.I.; Guerrero, J.M.; Garcia-Garcia, F.J.; Rodriguez-Manas, L.; Cruz-Chamorro, I.; Lardone, P.J.; Carrillo-Vico, A. Homocysteine Levels Are Associated with Bone Resorption in Pre-Frail and Frail Spanish Women: The Toledo Study for Healthy Aging. Exp. Gerontol. 2018, 108, 201–208. [CrossRef] [PubMed]

254. McLean, R.R.; Jacques, P.F.; Selhub, J.; Tucker, K.L.; Samelson, E.J.; Broe, K.E.; Hannan, M.T.; Cupples, L.A.; Kiel, D.P. Homocysteine as a Predictive Factor for Hip Fracture in Older Persons. N. Engl. J. Med. 2004, 350, 2042–2049. [CrossRef] [PubMed]

255. Van Meurs, J.B.; D’Onukshe-Rutten, R.A.; Pluijm, S.M.; van der Klift, M.; de Jonge, R.; Lindemans, J.; de Groot, L.C.; Hofman, A.; Witteman, J.C.; van Leeuwen, J.P.; et al. Homocysteine Levels and the Risk of Osteoporotic Fracture. N. Engl. J. Med. 2004, 350, 2033–2041. [CrossRef] [PubMed]

256. Shi, Z.; Guan, Y.; Huo, Y.R.; Liu, S.; Zhang, M.; Lu, H.; Yue, W.; Wang, J.; Ji, Y. Elevated Total Homocysteine Levels in Acute Ischemic Stroke Are Associated with Long-Term Mortality. Stroke 2015, 46, 2419–2425. [CrossRef] [PubMed]

257. Shankle, W.R.; Haras, J.; Barrentine, L.W.; Curole, M.V. Cerefolinnuc Therapy of Hyperhomocysteinemia Delays Cortical and White Matter Atrophy in Alzheimer’s Disease and Cerebrovascular Disease. J. Alzheimers Dis. 2016, 54, 1073–1084. [CrossRef] [PubMed]

258. Dawson, S.L.; Bowe, S.J.; Crowe, T.C. A Combination of Omega-3 Fatty Acids, Folic Acid and B-Group Vitamins Is Superior at Lowering Homocysteine Than Omega-3 Alone: A Meta-Analys. Nutr. Res. 2016, 36, 499–508. [CrossRef] [PubMed]
259. Mazza, A.; Cicero, A.F.; Ramazzina, E.; Lenti, S.; Schiavoni, L.; Gussoni, G. Nutraceutical Approaches to Homocysteine Lowering in Hypertensive Subjects at Low Cardiovascular Risk: A Multicenter, Randomized Clinical Trial. *J. Biol. Regul. Homeost. Agents* 2016, 30, 921–927. [PubMed]

260. Toole, J.F.; Malinow, M.R.; Chambless, L.E.; Spence, J.D.; Pettigrew, L.C.; Howard, V.J.; Sides, E.G.; Wang, C.H.; Stampfer, M. Lowering Homocysteine in Patients with Ischemic Stroke to Prevent Recurrent Stroke, Myocardial Infarction, and Death: The Vitamin Intervention for Stroke Prevention (Visp) Randomized Controlled Trial. *JAMA* 2004, 291, 565–575. [CrossRef] [PubMed]

261. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group; Armitage, J.M.; Bowman, L.; Clarke, R.J.; Wallendszus, K.; Bulbulia, R.; Rahimi, K.; Haynes, R.; Parish, S.; Sleight, P.; et al. Effects of Homocysteine-Lowering with Folic Acid Plus Vitamin B12 Vs Placebo on Mortality and Major Morbidity in Myocardial Infarction Survivors: A Randomized Trial. *JAMA* 2010, 303, 2486–2494. [CrossRef] [PubMed]

262. Cui, S.; Li, W.; Wang, P.; Lv, X.; Gao, Y.; Huang, G. Folic Acid Inhibits Homocysteine-Induced Cell Apoptosis in Human Umbilical Vein Endothelial Cells. *Mol. Cell Biochem.* 2018, 444, 77–86. [CrossRef] [PubMed]

263. Park, J.H.; Saposnik, G.; Ovbiagele, B.; Markovic, D.; Towfighi, A. Effect of B-Vitamins on Stroke Risk among Individuals with Vascular Disease Who Are Not on Antiplatelets: A Meta-Analysis. *Int. J. Stroke* 2016, 11, 206–211. [CrossRef] [PubMed]

264. Cui, S.; Li, W.; Lv, X.; Wang, P.; Gao, Y.; Huang, G. Folic Acid Supplementation Delays Atherosclerotic Lesion Development by Modulating Mcp1 and Vegf DNA Methylation Levels in Vivo and in Vitro. *Int. J. Mol. Sci.* 2017, 18, 990. [CrossRef] [PubMed]

265. Zeng, R.; Xu, C.H.; Xu, Y.N.; Wang, Y.L.; Wang, M. The Effect of Folate Fortification on Folic Acid-Based Homocysteine-Lowering Intervention and Stroke Risk: A Meta-Analysis. *Public Health Nutr.* 2015, 18, 1514–1521. [CrossRef] [PubMed]

266. VITATOPS Trial Study Group. B Vitamins in Patients with Recent Transient Ischaemic Attack or Stroke in the Vitamins to Prevent Stroke (Vitatops) Trial: A Randomised, Double-Blind, Parallel, Placebo-Controlled Trial. *Lancet Neurol.* 2010, 9, 855–865. [CrossRef]

267. Nigwekar, S.U.; Kang, A.; Zoungas, S.; Cass, A.; Gallagher, M.P.; Kulshrestha, S.; Navaneethan, S.D.; Perkovic, V.; Strippoli, G.F.; Jardine, M.J. Interventions for Lowering Plasma Homocysteine Levels in Dialysis Patients. *Cochrane Database Syst. Rev.* 2016, CD004683. [PubMed]

268. Marti-Carvajal, A.J.; Sola, I.; Lathyris, D.; Dayer, M. Homocysteine-Lowering Interventions for Preventing Cardiovascular Events. *Cochrane Database Syst. Rev.* 2017, 8, CD006612. [PubMed]

269. Clarke, R.; Bennett, D.; Parish, S.; Lewington, S.; Eussen, S.J.; Lewerin, C.; Stott, D.J.; Armitage, J.; Hankey, G.J.; et al. Effects of Homocysteine-Lowering with B Vitamins on Cognitive Aging: Meta-Analysis of 11 Trials with Cognitive Data on 22,000 Individuals. *Am. J. Clin. Nutr.* 2014, 100, 657–666. [CrossRef] [PubMed]

270. Lonn, E.; Yusuf, S.; Arnold, M.J.; Sheridan, P.; Pogue, J.; Micks, M.; McQueen, M.J.; Probstfield, J.; Fodor, G.; Held, C.; et al. Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease. *N. Engl. J. Med.* 2006, 354, 1567–1577. [PubMed]

271. Stott, D.J.; MacIntosh, G.; Lowe, G.D.; Rollins, A.; McMahon, A.D.; Langhorne, P.; Tait, R.C.; O’Reilly, D.S.; Spilg, E.G.; MacDonald, J.B.; et al. Randomized Controlled Trial of Homocysteine-Lowering Vitamin Treatment in Elderly Patients with Vascular Disease. *Am. J. Clin. Nutr.* 2005, 82, 1320–1326. [CrossRef] [PubMed]

272. Kang, J.H.; Cook, N.; Manson, J.; Buring, J.E.; Albert, C.M.; Grodstein, F. A Trial of B Vitamins and Cognitive Function among Women at High Risk of Cardiovascular Disease. *Am. J. Clin. Nutr.* 2008, 88, 1602–1610. [PubMed]

273. Andreeva, V.A.; Kesse-Guyot, E.; Barberger-Gateau, P.; Fezeu, L.; Hercberg, S.; Galan, P. Cognitive Function after Supplementation with B Vitamins and Long-Chain Omega-3 Fatty Acids: Ancillary Findings from the Su.Fol.Om3 Randomized Trial. *Am. J. Clin. Nutr.* 2011, 94, 278–286. [CrossRef] [PubMed]

274. Stone, K.L.; Lui, L.Y.; Christen, W.G.; Troen, A.M.; Bauer, D.C.; Kado, D.; Schambach, C.; Cummings, S.R.; Manson, J.E. Effect of Combination Folic Acid, Vitamin B6, and Vitamin B12 Supplementation on Fracture Risk in Women: A Randomized, Controlled Trial. *J. Bone Miner. Res.* 2017, 32, 2331–2338. [CrossRef] [PubMed]
275. Garcia Lopez, M.; Bonaa, K.H.; Ebbing, M.; Eriksen, E.F.; Gjesdal, C.G.; Nygard, O.; Tell, G.S.; Ueland, P.M.; Meyer, H.E. B Vitamins and Hip Fracture: Secondary Analyses and Extended Follow-up of Two Large Randomized Controlled Trials. *J. Bone Miner. Res.* 2017, 32, 1981–1989. [CrossRef] [PubMed]

276. Ntaios, G.; Savopoulo, C.; Karamitsos, D.; Economou, I.; Destanis, E.; Chryssogonidis, I.; Pidonia, I.; Zebekakis, P.; Polatides, C.; Sion, M.; et al. The Effect of Folic Acid Supplementation on Carotid Intima-Media Thickness in Patients with Cardiovascular Risk: A Randomized, Placebo-Controlled Trial. *Int. J. Cardiol.* 2010, 143, 16–19. [CrossRef] [PubMed]

277. Gomez, J.; Sanchez-Roman, I.; Gomez, A.; Sanchez, C.; Suarez, H.; Lopez-Torres, M.; Barja, G. Methionine and Homocysteine Modulate the Rate of Ros Generation of Isolated Mitochondria in vitro. *J. Bioenerg. Biomembr.* 2011, 43, 377–386. [CrossRef] [PubMed]

278. Yang, Z.; Yang, H.M.; Gong, D.Q.; Rose, S.P.; Pigorozliev, V.; Chen, X.S.; Wang, Z.Y. Transcriptome Analysis of Methionine Restriction Affects the Phenotypic and Transcriptional Response of Rainbow Trout (Oncorhynchus Mykiss) to Carbohydrate-Enriched Diets. *Br. J. Nutr.* 2013, 109, 402–412. [CrossRef] [PubMed]

279. Takumi, S.; Okamura, K.; Yagishita, H.; Sano, T.; Kobayashi, Y.; Nohara, K. The Effect of a Methyl-Deficient Diet on the Global DNA Methylation and the DNA Methylation Regulatory Pathways. *J. Appl. Toxicol.* 2015, 35, 1550–1556. [CrossRef] [PubMed]

280. Koz, S.T.; Etem, E.O.; Baydas, G.; Yuce, H.; Ozercan, H.I.; Kuloglu, T.; Koz, S.; Etem, A.; Demir, N. Effects of Resveratrol on Blood Homocysteine Level, on Homocysteine Induced Oxidative Stress, Apoptosis and Cognitive Dysfunctions in Rats. *Brain Res.* 2012, 1484, 29–38. [CrossRef] [PubMed]

281. Ma, S.C.; Zhang, H.P.; Jiao, Y.; Wang, Y.H.; Zhang, H.; Yang, X.L.; Yang, A.N.; Jiang, Y.D. Homocysteine-Induced Proliferation of Vascular Smooth Muscle Cells Occurs Via Pten Hypermethylation and Is Mitigated by Resveratrol. *Mol. Med. Rep.* 2018, 17, 5312–5319. [CrossRef] [PubMed]
293. Maugeri, A.; Barchitta, M.; Mazzone, M.G.; Giuliano, F.; Basile, G.; Agodi, A. Resveratrol Modulates Sirt1 and Dnmt Functions and Restores Line-1 Methylation Levels in Arpe-19 Cells under Oxidative Stress and Inflammation. *Int. J. Mol. Sci.* 2018, 19, 2118. [CrossRef] [PubMed]

294. Medina-Aguilar, R.; Pérez-Plasencia, C.; Marchat, L.A.; Gariglio, P.; García Mena, J.; Rodríguez Cuevas, S.; Ruiz-García, E.; Astudillo-de la Vega, H.; Hernández Juárez, J.; Flores-Pérez, A.; et al. Methylation Landscape of Human Breast Cancer Cells in Response to Dietary Compound Resveratrol. *PLoS ONE* 2016, 11, e0157866. [CrossRef] [PubMed]

295. Zanatta, A.; Cecatto, C.; Ribeiro, R.T.; Amaral, A.U.; Wyse, A.T.; Leipnitz, G.; Wajner, M. Methionine Restriction Decreases Oxidative DNA Damage in Rat Liver and Heart. *J. Bioenerg. Biomembr.* 2018, 55, 5868–5878. [CrossRef] [PubMed]

296. Sanz, A.; Caro, P.; Ayala, V.; Portero-Otin, M.; Pamplona, R.; Barja, G. Methionine Restriction Decreases Mitochondrial Oxygen Radical Generation and Leak as Well as Oxidative Damage to Mitochondrial DNA and Proteins. *FASEB J.* 2006, 20, 1064–1073. [CrossRef] [PubMed]

297. Gomez, J.; Caro, P.; Sanchez, I.; Naudi, A.; Jove, M.; Portero-Otin, M.; Lopez-Torres, M.; Pamplona, R.; Barja, G. Effect of Methionine Dietary Supplementation on Mitochondrial Oxygen Radical Generation and Oxidative DNA Damage in Rat Liver and Heart. *J. Bioenerg. Biomembr.* 2009, 41, 309–321. [CrossRef] [PubMed]

298. Yang, A.N.; Zhang, H.P.; Sun, Y.; Yang, X.L.; Wang, N.; Zhu, G.; Zhang, H.; Xu, H.; Ni, H.; Ren, W.; Duraipandiyan, V.; Chen, S.; Al-Dhabi, N.A.; et al. Methionine Restriction Affects Oxidative Stress and Dnmt Functions and Restores Line-1 Methylation Levels in Arpe-19 Cells under Oxidative Stress and Inflammation. *Int. J. Mol. Sci.* 2018, 19, 3106. [CrossRef] [PubMed]

299. Su, W.; Zhang, H.; Ying, Z.; Li, Y.; Zhou, L.; Wang, F.; Zhang, L.; Wang, T. Effects of Dietary L-Methionine Supplementation on Intestinal Integrity and Oxidative Status in Intrauterine Growth-Retarded Weanling Piglets. *Eur. J. Nutr.* 2017. [CrossRef] [PubMed]

300. Aissa, A.F.; Amaral, C.L.D.; Venancio, V.P.; Machado, C.D.S.; Hernandes, L.C.; Santos, P.; Curi, R.; Bianchi, M.L.P.; Antunes, L.M.G. Methionine-Supplemented Diet Affects the Expression of Cardiovascular Disease-Related Genes Via DNMT1 in ApoE(−/−) Mice. *FEBS Lett.* 2015, 589, 3998–4009. [CrossRef] [PubMed]

301. Mioussse, I.R.; Pathak, R.; Garg, S.; Skinner, C.M.; Melnyk, S.; Pavliv, O.; Hendrickson, H.; Landes, R.D.; Lumen, A.; Tackett, A.J.; et al. High-Methionine Diets Accelerate Atherosclerosis by Hhcy-Mediated Fabp4 Gene Demethylation Pathway Via DNMT1 in ApoE(−/−) Mice. *FEBS Lett.* 2015, 589, 3998–4009. [CrossRef] [PubMed]

302. Su, W.; Zhang, H.; Ying, Z.; Li, Y.; Zhou, L.; Wang, F.; Zhang, L.; Wang, T. Effects of Dietary L-Methionine Supplementation on Intestinal Integrity and Oxidative Status in Intrauterine Growth-Retarded Weanling Piglets. *Eur. J. Nutr.* 2017. [CrossRef] [PubMed]

303. Parrish, R.R.; Buckingham, S.C.; Mascia, K.L.; Johnson, J.J.; Matyjasik, M.M.; Lockhart, R.M.; Lubin, F.D. Methionine Increases Bdnf DNA Methylation and Improves Memory in Epilepsy. *Ann. Clin. Transl. Neurol.* 2015, 2, 401–416. [CrossRef] [PubMed]

304. Wright, K.N.; Hollis, F.; Duclot, F.; Dossat, A.M.; Strong, C.E.; Francis, T.C.; Mercer, R.; Feng, J.; Dietz, D.M.; Lobo, M.K.; et al. Methyl Supplementation Attenuates Caffeine-Seeking Behaviors and Cocaine-Induced C-Fos Activation in a DNA Methylation-Dependent Manner. *J. Neurosci.* 2015, 35, 8948–8958. [CrossRef] [PubMed]

305. Maddineni, S.; Nichenametla, S.; Sinha, R.; Wilson, R.P.; Richie, J.P., Jr. Methionine Restriction Affects Oxidative Stress and Glutathione-Related Redox Pathways in the Rat. *Exp. Biol. Med.* 2013, 238, 392–399. [CrossRef] [PubMed]

306. Liu, G.; Yu, L.; Fang, J.; Hu, C.A.; Yin, J.; Ni, H.; Ren, W.; Duraipandiyan, V.; Chen, S.; Al-Dhabi, N.A.; et al. Methionine Restriction on Oxidative Stress and Immune Response in Dss-Induced Colitis Mice. *Oncotarget* 2017, 8, 44511–44520. [CrossRef] [PubMed]

307. Ying, Y.; Yun, J.; Guoyao, W.; Kaji, S.; Zhaoli, D.; Zhenlong, W. Dietary L-Methionine Restriction Decreases Oxidative Stress in Porcine Liver Mitochondria. *Exp. Gerontol.* 2015, 65, 35–41. [CrossRef] [PubMed]

308. Sanchez-Roman, I.; Gomez, A.; Perez, I.; Sanchez, C.; Suarez, H.; Naudi, A.; Jove, M.; Lopez-Torres, M.; Pamplona, R.; Barja, G. Effects of Aging and Methionine Restriction Applied at Old Age on ROS Generation and Oxidative Damage in Rat Liver Mitochondria. *Biotheriogenology* 2012, 13, 399–411. [CrossRef] [PubMed]
309. Sanchez-Roman, I.; Gomez, A.; Gomez, J.; Suarez, H.; Sanchez, C.; Naudi, A.; Ayala, V.; Portero-Otin, M.; Lopez-Torres, M.; Pamplona, R.; et al. Forty Percent Methionine Restriction Lowers DNA Methylation, Complex I. Ros Generation, and Oxidative Damage to Mtdna and Mitochondrial Proteins in Rat Heart. *J. Bioenerg. Biomembr.* 2011, 43, 699–708. [CrossRef] [PubMed]

310. Pogribny, I.P.; Basnakian, A.G.; Miller, B.J.; Lopatina, N.G.; Poirier, L.A.; James, S.J. Breaks in Genomic DNA and within the P53 Gene Are Associated with Hypomethylation in Livers of Folate/Methyl-Deficient Rats. *Cancer Res.* 1995, 55, 1894–1901. [PubMed]

311. Mattocks, D.A.; Mentch, S.J.; Shneyder, J.; Ables, G.P.; Sun, D.; Richie, J.P., Jr.; Locasale, J.W.; Nicken, P.; Empl, M.T.; Gerhard, D.; Hausmann, J.; Steinberg, P. Methionine Restriction Inhibits Chemically-Induced Malignant Transformation in the Balb/C 3T3 Cell Transformation Assay. *Food Chem. Toxicol.* 2016, 95, 196–202. [CrossRef] [PubMed]

312. Johnson, J.E.; Johnson, F.B. Methionine Restriction Activates the Retrograde Response and Confers Both Stress Tolerance and Lifespan Extension to Yeast, Mouse and Human Cells. *PLoS ONE* 2014, 9, e97729. [CrossRef] [PubMed]

313. Orgeron, M.L.; Stone, K.P.; Wanders, D.; Cortez, C.C.; Van, N.T.; Gettys, T.W. The Impact of Dietary Methionine Restriction on Biomarkers of Metabolic Health. *Prog. Mol. Biol. Transl. Sci* 2014, 121, 351–376. [PubMed]

314. Hoffman, D.R.; Marion, D.W.; Cornatzer, W.E.; Duerre, J.A. S-Adenosylmethionine and S-Adenosylhomocysteine Metabolism in Isolated Rat Liver. Effects of L-Methionine, L-Homocysteine, and Adenosine. *J. Biol. Chem.* 1980, 255, 10822–10827. [PubMed]

315. Orentreich, N.; Matias, J.R.; DeFelice, A.; Zimmerman, J.A. Low Methionine Ingestion by Rats Extends Life Span. *J. Nutr.* 1993, 123, 269–274. [PubMed]

316. James, S.J.; Melnyk, S.; Pogribna, M.; Pogribny, I.P.; Caudill, M.A. Elevation in S-Adenosylhomocysteine and DNA Hypomethylation: Potential Epigenetic Mechanism for Homocysteine-Related Pathology. *J. Nutr.* 2002, 132, 2361S–2366S. [CrossRef] [PubMed]

317. Hoffman, D.R.; Marion, D.W.; Cornatzer, W.E.; Duerre, J.A. S-Adenosylmethionine and S-Adenosylhomocysteine Are Associated with Retinal Microvascular Abnormalities: The Hoorn Study. *Clin. Epigenet.* 2015, 7, 14. [CrossRef] [PubMed]

318. Chang, P.Y.; Lu, S.C.; Lee, C.M.; Chen, Y.J.; Dugan, T.A.; Huang, W.H.; Chang, S.F.; Liao, W.S.; Chen, C.H.; Lee, Y.T. Homocysteine Inhibits Arterial Endothelial Cell Growth through Transcriptional Downregulation of Fibroblast Growth Factor-2 Involving G Protein and DNA Methylation. *Circ. Res.* 2008, 102, 933–941. [CrossRef] [PubMed]

319. Van Hecke, M.V.; Dekker, J.M.; Nijpels, G.; Teerlink, T.; Jakobs, C.; Stolk, R.P.; Heine, R.J.; Bouter, L.M.; Polak, B.C.; Stehouwer, C.D. Homocysteine, S-Adenosylmethionine and Modulating the Methylation of Srebf1 and Ldlr Genes. *Clin. Epigenet.* 2015, 14. [CrossRef] [PubMed]

320. Bawazeer, N.; Al-Daghri, N.M.; McTernan, P.G.; et al. Vitamin B12 Insufficiency Induces Cholesterol Biosynthesis by Limiting S-Adenosylmethionine and Modulating the Methylation of Srebf1 and Ldlr Genes. *Food Chem. Toxicol.* 2011, 49, 196–202. [CrossRef] [PubMed]

321. Yamamoto, D.; Shima, K.; Matsuo, K.; Nishioka, T.; Chen, C.Y.; Hu, G.F.; Sasaki, A.; Tsuji, T. Ornithine Decarboxylase Antizyme Induces Hypomethylation of Genome DNA and Histone H3 Lysine 9 Dimethylation (H3K9me2) in Human Oral Cancer Cell Line. *PLoS ONE* 2010, 5, e12554. [CrossRef] [PubMed]

322. Tsuji, T.; Usui, S.; Aida, T.; Tachikawa, T.; Hu, G.F.; Sasaki, A.; Matsumura, T.; Todd, R.; Wong, D.T. Induction of Epithelial Differentiation and DNA Demethylation in Hamster Malignant Oral Keratinocyte by Ornithine Decarboxylase Antizyme. *Oncogene* 2001, 20, 24–33. [CrossRef] [PubMed]

323. Pegg, A.E.; Wang, X.; Schwartz, C.E.; McCloskey, D.E. Spermine Synthase Activity Affects the Content of Decarboxylated S-Adenosylmethionine. *Biochem. J.* 2011, 433, 139–144. [CrossRef] [PubMed]

324. Shantz, L.M.; Holm, I.; Janne, O.A.; Pegg, A.E. Regulation of S-Adenosylmethionine Decarboxylase Activity by Alterations in the Intracellular Polyamine Content. *Biochem. J.* 1992, 288 Pt. 2, 511–518. [CrossRef]

325. Papazafiri, P.; Osborne, H.B. Effect of α-Difluoromethylornithine on DNA Methylation in Murine Erythroleukemic Cells. Relationship to Stimulation of Induced Differentiation. *Biochem. J.* 1987, 242, 479–483. [CrossRef] [PubMed]
326. Poomipark, N.; Flatley, J.E.; Hill, M.H.; Mangnall, B.; Azar, E.; Grabowski, P.; Powers, H.J. Methyl Donor Status Influences Dmr Expression and Global DNA Methylation in Cervical Cancer Cells. *Asiam Pac. J. Cancer Prev.* 2016, 17, 3213–3222. [PubMed]

327. Minoi, N.; Carmona-Gutierrez, D.; Madeo, F. Polyamines in Aging and Disease. *Aging (Albany NY)* 2011, 3, 716–732. [CrossRef] [PubMed]

328. Casillas, M.A., Jr.; Lopatina, N.; Andrews, L.G.; Tollefsbol, T.O. Transcriptional Control of the DNA Methyltransferases Is Altered in Aging and Neoplastically-Transformed Human Fibroblasts. *Mol. Cell Biochem.* 2003, 252, 33–43. [CrossRef] [PubMed]

329. Lopatina, N.; Haskell, J.F.; Butterbach, K.; Muller, H.; Bewerunge-Hudler, M.; Brenner, H. Cross-Sectional and Longitudinal Differences at Regulatory Elements Are Associated with the Cancer Risk Factor Age. *Breast Cancer Res.* 2016, 18, 33–43. [CrossRef] [PubMed]

330. Lu, Q.; Kaplan, M.; Ray, D.; Ray, D.; Zacharek, S.; Gutsch, D.; Richardson, B. Demethylation of ITGAL (Cd11a) Regulatory Sequences in Systemic Lupus Erythematosus. *Arthritis Rheum.* 2002, 46, 1282–1291. [CrossRef] [PubMed]

331. Perez, R.F.; Tejedor, J.R.; Bayon, G.F.; Fernandez, A.F.; Fraga, M.F. Distinct Chromatin Signatures of DNA Hypomethylation in Aging and Cancer. *Aging Cell* 2018, 17, e12744. [CrossRef] [PubMed]

332. Zeng, Q.; Chen, X.; Zhu, Q.; Yao, Y.; Zhao, Y.; Luan, F. Methylation of the Genes Rod1, Nlrc5, and Hkr1 Is Associated with Aging in Hainan Centenarians. *BMCMed. Genom.* 2018, 11, 7. [CrossRef] [PubMed]

333. Florath, I.; Butterbach, K.; Muller, H.; Bewerunge-Hudler, M.; Brenner, H. Cross-Sectional and Longitudinal Changes in DNA Methylation with Age: An Epigenome-Wide Analysis Revealing over 60 Novel Age-Associated Cpg Sites. *Hum. Mol. Genet.* 2014, 23, 1186–1201. [CrossRef] [PubMed]

334. McClay, J.L.; Aberg, K.A.; Clark, S.L.; Nerella, S.; Kumar, G.; Xie, L.Y.; Hudson, A.D.; Harada, A.; Hultman, C.M.; Magnusson, P.K.; et al. A Methylome-Wide Study of Aging Using Massively Parallel Sequencing of the Methyl-Cpg-Enriched Genomic Fraction from Blood in over 700 Subjects. *Hum. Mol. Genet.* 2014, 23, 1175–1185. [CrossRef] [PubMed]

335. Aliisch, R.S.; Barwick, B.G.; Chopra, P.; Myrick, L.K.; Satten, G.A.; Connelly, K.N.; Warren, S.T. Age-Associated DNA Methylation in Pediatric Populations. *Genome Res.* 2012, 22, 623–632. [CrossRef] [PubMed]

336. Richardson, B.C. Role of DNA Methylation in the Regulation of Cell Function: Autoimmunity, Aging and Cancer. *J. Nutr.* 2002, 132, 2401S–2405S. [CrossRef] [PubMed]

337. Hatazawa, Y.; Ono, Y.; Hirose, Y.; Kanai, S.; Fujii, N.L.; Machida, S.; Nishino, I.; Shimizu, T.; Okano, M.; Kamei, Y.; et al. Reduced Dnmt3a Increases Gdf5 Expression with Suppressed Satellite Cell Differentiation and Impaired Skeletal Muscle Regeneration. *FASEB J.* 2018, 32, 1452–1467. [CrossRef] [PubMed]

338. De Magalhaes, J.P. How Ageing Processes Influence Cancer. *Nat. Rev. Cancer* 2013, 13, 357–365. [CrossRef] [PubMed]

339. Johnson, K.C.; Houseman, E.A.; King, J.E.; Christensen, B.C. Normal Breast Tissue DNA Methylation Differences at Regulatory Elements Are Associated with the Cancer Risk Factor Age. *Breast Cancer Res.* 2017, 19, 81. [CrossRef] [PubMed]

340. Galamb, O.; Kalmár, Á.; Barták, B.K.; Patai, Á.V.; Leiszter, K.; Péterfia, B.; Wichmann, B.; Vavez, G.; Veres, G.; Tülassay, Z.; et al. Aging Related Methylation Influences the Gene Expression of Key Control Genes in Colorectal Cancer and Adenoma. *World J. Gastroenterol.* 2016, 22, 10325–10340. [CrossRef] [PubMed]

341. Okuchi, Y.; Imajo, M.; Mizuno, R.; Kamioka, Y.; Miyoshi, H.; Taketo, M.M.; Nagayama, S.; Sakai, Y.; Matsuda, M. Identification of Aging-Associated Gene Expression Signatures That Precede Intestinal Tumorigenesis. *PLoS ONE* 2016, 11, e0162300. [CrossRef] [PubMed]

342. Lin, Q.; Wagner, W. Epigenetic Aging Signatures Are Coherently Modified in Cancer. *PLoS Genet.* 2015, 11, e1005334. [CrossRef] [PubMed]

343. Wada, H.; Wada, U.F.; Mano, H.; Higashiguchi, M.; Haba, R.; Watanabe, S.; Udaka, S. Effects of Dietary Polyamines on the Promotion of Mammary Tumor in Rats. *J. Health Sci.* 2002, 48, 376–380. [CrossRef]

344. He, T.C.; Sparks, A.B.; Rago, C.; Hermeking, H.; Zawel, L.; da Costa, L.T.; Morin, P.J.; Vogelstein, B.; Kinzler, K.W. Identification of C-Myc as a Target of the Apc Pathway. *Science* 1998, 281, 1509–1512. [CrossRef] [PubMed]

345. Bello-Fernandez, C.; Packham, G.; Cleveland, J.L. The Ornithine Decarboxylase Gene Is a Transcriptional Target of C-Myc. *Proc. Natl. Acad. Sci. USA* 1993, 90, 7804–7808. [CrossRef] [PubMed]
346. Pena, A.; Reddy, C.D.; Wu, S.; Hickok, N.J.; Reddy, E.P.; Yumet, G.; Soprano, D.R.; Soprano, K.J. Regulation of Human Ornithine Decarboxylase Expression by the C-Myc.Max Protein Complex. J. Biol. Chem. 1993, 268, 27277–27285. [PubMed]

347. Shukla-Dave, A.; Castillo-Martin, M.; Chen, M.; Lobo, J.; Gladoun, N.; Collazo-Lorduy, A.; Khan, F.M.; Ponomarev, V.; Yi, Z.; Zhang, W.; et al. Ornithine Decarboxylase Is Sufficient for Prostate Tumorigenesis via Androgen Receptor Signaling. Am. J. Pathol. 2016, 186, 3131–3145. [CrossRef] [PubMed]

348. Auvinen, M.; Paasinen, A.; Andersson, L.C.; Holttta, E. Ornithine Decarboxylase Activity Is Critical for Cell Transformation. Nature 1992, 360, 355–358. [CrossRef] [PubMed]

349. Erdman, S.H.; Ignatenko, N.A.; Powell, M.B.; Blohm-Mangone, K.A.; HolubeC, H.; Guillen-Rodriguez, J.M.; Gerner, E.W. Apc-Dependent Changes in Expression of Genes Influencing Polyamine Metabolism, and Consequences for Gastrointestinal Carcinogenesis, in the Min Mouse. Carcinogenesis 1999, 20, 1709–1713. [CrossRef] [PubMed]

350. Megosh, L.; Halpern, M.; Farkash, E.; O’Brien, T.G. Analysis of Ras Gene Mutational Spectra in Epidermal Papillomas from K6/Odc Transgenic Mice. Mol. Carcinog. 1998, 22, 145–149. [CrossRef]

351. Moshier, J.A.; Malecka-Panas, E.; Geng, H.; Dosescu, J.; Tureaud, J.; Skunca, M.; Majumdar, A.P. Ornithine Decarboxylase Transformation of NIH/3T3 Cells Is Mediated by Altered Epidermal Growth Factor Receptor Activity. Cancer Res. 1995, 55, 5358–5365. [PubMed]

352. Shantz, L.M.; Pegg, A.E. Ornithine Decarboxylase Induction in Transformation by H-Ras and Rhoa. Cancer Res. 1998, 58, 2748–2753. [PubMed]

353. Holttta, E.; Sistonen, L.; Alitalo, K. The Mechanisms of Ornithine Decarboxylase Deregulation in C-Ha-Ras Oncogene-Transformed Nih 3T3 Cells. J. Biol. Chem. 1988, 263, 4500–4507. [PubMed]

354. Clifford, A.; Morgan, D.; Yuspa, S.H.; Soler, A.P.; Gilmour, S. Role of Ornithine Decarboxylase in Epidermal Tumorigenesis. Cancer Res. 1995, 55, 1680–1686. [PubMed]

355. Hibshoosh, H.; Johnson, M.; Weinstein, I.B. Effects of Overexpression of Ornithine Decarboxylase (Odc) on Growth Control and Oncogene-Induced Cell Transformation. Oncogene 1991, 6, 739–743.

356. O’Brien, T.G.; Megosh, L.C.; Gilliard, G.; Soler, A.P. Ornithine Decarboxylase Overexpression Is a Sufficient Condition for Tumor Promotion in Mouse Skin. Cancer Res. 1997, 57, 2630–2637. [PubMed]

357. Ito, K.; Kashiwagi, K.; Watanabe, S.; Kameji, T.; Hayashi, S.; Igarashi, K. Influence of the 5′-Untranslated Region of Ornithine Decarboxylase Mrna and Spermidine on Ornithine Decarboxylase Synthesis. J. Biol. Chem. 1990, 265, 13036–13041. [PubMed]

358. Kashiwagi, K., Ito, K.; Igarashi, K. Spermidine Regulation of Ornithine Decarboxylase Synthesis by a Gc-Rich Sequence of the 5′-Untranslated Region. Biochem. Biophys. Res. Commun. 1991, 178, 815–822. [CrossRef]

359. Lovkvist, E.; Sistonen, L.; Alitalo, K. The Mechanisms of Ornithine Decarboxylase Deregulation in C-Ha-Ras Oncogene-Transformed Nih 3T3 Cells. J. Biol. Chem. 1988, 263, 4500–4507. [PubMed]

360. Vargas, A.J.; Wertheim, B.C.; Gerner, E.W.; Thomson, C.A.; Rock, C.L.; Thompson, P.A. Dietary Polyamine Intake and Colorectal Cancer Risk in Postmenopausal Women. Am. J. Clin. Nutr. 2015, 102, 411–419. [CrossRef] [PubMed]

361. Vargas, A.J.; Asbeck, E.L.; Wertheim, B.C.; Wallace, R.B.; Neuhauser, M.L.; Thomson, C.A.; Thompson, P.A. Dietary Polyamine Intake and Colorectal Cancer Risk in Postmenopausal Women. Am. J. Clin. Nutr. 2015, 102, 133–141. [CrossRef] [PubMed]

362. Huidobro, C.; Fernandez, A.F.; Fraga, M.F. Aging Epigenetics: Causes and Consequences. Mol. Aspects Med. 2013, 34, 765–781. [CrossRef] [PubMed]

363. Huidobro, C.; Fernandez, A.F.; Fraga, M.F. Aging Epigenetics: Causes and Consequences. Mol. Aspects Med. 2013, 34, 765–781. [CrossRef] [PubMed]

364. Maegawa, S.; Gough, S.M.; Watanabe-Okochi, N.; Lu, Y.; Zhang, N.; Castoro, R.J.; Estecio, M.R.; Jelinek, J.; Liang, S.; Kitamura, T.; et al. Age-Related Epigenetic Drift in the Pathogenesis of Mds and Aml. Genome Res. 2014, 24, 580–591. [CrossRef] [PubMed]

365. Borghini, A.; Cervelli, T.; Galli, A.; Andreassi, M.G. DNA Modifications in Atherosclerosis: From the Past to the Future. Atherosclerosis 2013, 230, 202–209. [CrossRef] [PubMed]

366. Vlaming, H.; van Leeuwen, F. Crosstalk between Aging and the Epigenome. Epigenomics 2012, 4, 5–7. [CrossRef] [PubMed]
368. Nojima, M.; Iwasaki, M.; Kasuga, Y.; Yokoyama, S.; Onuma, H.; Nishimura, H.; Kusama, R.; Yoshida, T.; Tsugane, S. Correlation between Global Methylation Level of Peripheral Blood Leukocytes and Serum C Reactive Protein Level Modified by Mthfr Polymorphism: A Cross-Sectional Study. *BMC Cancer* **2018**, *18*, 184. [CrossRef] [PubMed]

369. Iwaya, C.; Kitajima, H.; Yamamoto, K.; Maeda, Y.; Sonoda, N.; Shibata, H.; Inoguchi, T. DNA Methylation of the Klf14 Gene Region in Whole Blood Cells Provides Prediction for the Chronic Inflammation in the Adipose Tissue. *Biochem. Biophys. Res. Commun.* **2018**, *497*, 908–915. [CrossRef] [PubMed]

370. Fang, G.; Zhang, Q.H.; Tang, Q.; Jiang, Z.; Xing, S.; Li, J.; Pang, Y. Comprehensive Analysis of Gene Expression and DNA Methylation Datasets Identify Valuable Biomarkers for Rheumatoid Arthritis Progression. *Oncotarget* **2018**, *9*, 2977–2983. [CrossRef] [PubMed]

371. Kan, S.; Wu, J.; Sun, C.; Hao, J.; Wu, Z. Correlation between Rage Gene Promoter Methylation and Diabetic Retinal Inflammation. *Exp. Ther. Med.* **2018**, *15*, 242–246. [CrossRef] [PubMed]

© 2018 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).